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Abstract
Methadone and buprenorphine/naloxone are the two recommended pharmacotherapies for the treatment
of opioid dependence, having been demonstrated to be effective in numerous clinical trials. While
methadone has been an approved treatment for opioid dependence for that past 50 years,
buprenorphine/naloxone is a newer substance that was only approved for use in 2002. This mixedmethods study utilizes a comprehensive conceptual framework of neoinstitutional theory and institutional
logics to explore possible factors that might predict adoption of medication-assisted treatment.
First, in-depth qualitative interviews with managerial level staff at substance abuse treatment centers
were conducted. The interviews were semi-structured and explored perceptions of treatment philosophy,
the merging of substance abuse and mental health, managed care, services, funding, licensing and
accreditation and personal and professional networks. Next, logistic regression models were used to
explore possible predictors of medication-assisted treatment. The National Treatment Center Study
(NTCS), a nationally representative survey of private substance abuse treatment facilities conducted
between 2002-2004, was used in this study, allowing for the exploration of early adoption of
buprenorphine/naloxone.
Findings from the qualitative interviews suggested that the two medications are viewed differently and
should therefore be explored separately. Findings from the logistic analysis of the NTCS supported this
distinction. The proportion of clients with a primary diagnosis of opiate dependence or abuse was the
only factor positively associated with both the early adoption of buprenorphine/naloxone and methadone
provision. The program's proportion of managed care funding was the only other significant predictor for
early adoption of buprenorphine/naloxone. Accreditation by JACHO, proportion of clients who are women
and past organizational participation in research, all positively predicted methadone provision, while the
proportion of counselors with a master's degree or higher negatively predicted it.
The results indicate that coercive and normative institutional forces, as well as the institutional logics
operating on organizations and the organizational networks they are embedded in, impact service
provision and adoption of innovation. To promote adoption of pharmacotherapies into treatment,
attention must be paid to the unique barriers and opportunities facing the adoption of each medication.
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ABSTRACT
ORGANIZATIONAL CORRELATES OF MEDICATION-ASSISTED TREATMENT
(MAT) IN SUBSTANCE ABUSE TREATMENT FACILITIES: EXAMINING HOW
INSTITUTIONAL FORCES SHAPE TREATMENT
Maayan Lawental Schori
Toorjo Ghose
Methadone and buprenorphine/naloxone are the two recommended
pharmacotherapies for the treatment of opioid dependence, having been demonstrated to
be effective in numerous clinical trials. While methadone has been an approved treatment
for opioid dependence for that past 50 years, buprenorphine/naloxone is a newer
substance that was only approved for use in 2002. This mixed-methods study utilizes a
comprehensive conceptual framework of neoinstitutional theory and institutional logics
to explore possible factors that might predict adoption of medication-assisted treatment.
First, in-depth qualitative interviews with managerial level staff at substance
abuse treatment centers were conducted. The interviews were semi-structured and
explored perceptions of treatment philosophy, the merging of substance abuse and mental
health, managed care, services, funding, licensing and accreditation and personal and
professional networks. Next, logistic regression models were used to explore possible
predictors of medication-assisted treatment. The National Treatment Center Study
(NTCS), a nationally representative survey of private substance abuse treatment facilities
conducted between 2002-2004, was used in this study, allowing for the exploration of
early adoption of buprenorphine/naloxone.
Findings from the qualitative interviews suggested that the two medications are
viewed differently and should therefore be explored separately. Findings from the logistic
analysis of the NTCS supported this distinction. The proportion of clients with a primary
diagnosis of opiate dependence or abuse was the only factor positively associated with
both the early adoption of buprenorphine/naloxone and methadone provision. The
program’s proportion of managed care funding was the only other significant predictor
for early adoption of buprenorphine/naloxone. Accreditation by JACHO, proportion of
clients who are women and past organizational participation in research, all positively
predicted methadone provision, while the proportion of counselors with a master’s degree
or higher negatively predicted it.
The results indicate that coercive and normative institutional forces, as well as the
institutional logics operating on organizations and the organizational networks they are
embedded in, impact service provision and adoption of innovation. To promote adoption
of pharmacotherapies into treatment, attention must be paid to the unique barriers and
opportunities facing the adoption of each medication.
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Organizational correlates of medication-assisted treatment (MAT)
for opioid dependence in substance abuse treatment facilities:
Examining how institutional forces shape treatment
Maayan Lawental Schori
Chapter 1
Introduction
According to the latest national data available from 2010, 22.1 million persons
ages 12 and older suffered from a substance use disorder (abuse or dependence) in the
last year, corresponding to 8.7% of the U.S. population (Substance Abuse and Mental
Health Services Administration [SAMHSA], 2011a). These people, in addition to those
already receiving treatment in at a specialty facility, are classified by SAMSHA as
needing treatment. Of the 23.1 persons classified as needing treatment, only 4.1 million
received it; and for over half of those who did receive treatment, it was in the form of
self-help groups. Therefore, the vast majority of people needing treatment do not receive
any (SAMHSA, 2011a). This represents the lowest treatment penetration of any illness or
condition (McGlynn et al., 2003). According to the latest data available, submitted to the
Office of National Drug Control Policy (ONDCP) the economic costs associated with
illicit drug use were estimated to be over $193 billion in 2007. Of this amount, only $3.7
billion was spent on any form of treatment (National Drug Intelligence Center, 2011).
Several decades worth of research have demonstrated that medication-assisted
treatment, particularly when combined with counseling, improves treatment outcomes for
clients suffering from substance use disorders (Anton, Moak, Waid, Latham, Malcolm, &
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Dian, 1999; Johnson, Eisenberg, Stitzer, Strain, Liebson, & Bigelow, 1995; Ling et al.
1998; Monti et al. 2001; O’Malley, Jaffe, Chang, Schottenfeld, Meyer, & Rounsaville,
1992; Volpicelli, Alterman, Hayashida, Volpicelli, J.R.; Alterman, A.I.; Hayashida, M. &
O’Brien & O’Brien, 1992). Research has also shown that use of medication-assisted
treatment results in reduced mortality and criminal activity rates (Greenfield & Fountain
2000; Saxon & McCarty 2005; Woody et al. 2008). For instance, in a meta-analysis of
three decades worth of research on methadone maintenance treatment (MMT), a
pharmacotherapy used for treating persons struggling with opioid dependence, Marsch
(1998) found that this form of treatment significantly reduced levels of illicit opiate use,
HIV risk behavior, and criminal activity. The National Institute on Drug Abuse (NIDA,
2009) and the World Health Organization (WHO, 2004) recommend methadone
maintenance as the standard of treatment and care for opiate abuse. Though methadone is
legal in all 50 U.S. States, issues remain surrounding proper dosage and length of
maintenance. Buprenorphine/naloxone (aka Subutex® or Suboxone®), a newer
pharmacotherapy for treatment of opioid dependence was approved for use in the U.S. in
2002 and has been the focus of many recent clinical trials which have demonstrated its
effectiveness (e.g. Amass et al., 2004; Fischer et al., 1999; Fudula et al., 2003; Johnson,
Chutuape, Strain, Walsh, Stitzer, & Bigelow 2000; Ling et al., 2005; Ling, Wesson,
Charuvastra, & Klett, 1996; Lintzeris, Bell, Bammer, Jolley, & Rushworth, 2002). While
additional pharmacotherapies are being developed and tested and much attention has
been focused in recent research on their effectiveness, this thesis will focus on the abovementioned opioid replacement therapies, methadone and buprenorphine/naloxone.
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Substance abuse treatment organizations have often been criticized for their slow
adoption of new practices (Kimberly & McLellan, 2006; Knudsen & Roman, 2004;
Lamb, Greenlick, & McCarthy, 1998; Sloboda & Schildhaus, 2002). While previous
studies have looked at organizational processes in service provision (e.g. D’Aunno, 2006;
D’Aunno, Sutton, & Price, 1991; Guerrero, 2009; Roman & Johnson, 2002; Simpson &
Flynn, 2007), the influence of organizational factors on treatment has seldom been
interpreted in the context of organizational theory. With the notable exception of
D’Aunno and colleagues (D’Aunno, Sutton, & Price, 1991; D’Aunno, Vaughn, &
McElroy, 1999), and very recent work by Roman and colleagues (Savage, Abraham,
Knudsen, Tothrauff, & Roman, 2012) most scholars do not employ a comprehensive
conceptual framework to identify organizational predictors, or to interpret results. As a
result, research on organizational research in substance abuse treatment has tended to
focus on top-down institutional forces shaping treatment. Scholars have largely
underplayed the role of individual organizational actors, a focus of recent works in the
field of institutional logics (Thornton & Ocasio, 2008). An atheoretical approach that is
based on examining only those organizational factors which have been found to be
significant predictors by previous research results in: (a) conscribing the universe of
possible organizational predictors to those that have already been examined, thus
ignoring the salience of new factors and unique processes predicted by theory, (b) failing
to understand the complex and often contradictory processes that shape organizational
behavior, and (c) undermining the theoretical framework underpinning the field of
organizational substance abuse treatment research.
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To improve the breadth of factors considered and the analytic methods used in
explaining the provision of medication-assisted treatment, this thesis will apply the theory
of institutional logics to examine an expanded set of organizational and institutional
correlates of medication-assisted treatment in substance abuse treatment facilities, using a
mixed methods approach. First, 30 qualitative interviews with decision makers in
substance abuse treatment facilities will be used to develop an expanded set of
organizational factors which could reasonably be expected to predict the provision of
medication-assisted treatment. The interviews will also be used to frame the discussion of
the results. Second, an additional analysis of The National Treatment Center Study
(NTCS), a nationally representative dataset of substance abuse treatment facilities, will
be conducted.
The NTCS is the largest, most contemporary and comprehensive source available
examining organizational variables. The survey to be analyzed in this thesis comes from
405 private substance abuse treatment facilities in the U.S., conducted between 20022004 by the Institute of Behavioral Research at the University of Georgia. This survey
collected data pertaining to changes organizations, structure, staffing, and service
delivery patterns in substance abuse treatment facilities. The data will be used to examine
the extent to which factors identified by theory, previous literature and the qualitative
interviews, contribute to explaining the organizational adoption of medication-assisted
treatment. Furthermore, since buprenorphine/naloxone was approved for use in 2002
(Amass et al., 2004; Brown, 2004; Ling et al., 2009; NIDA, 2006), this dataset provides a
unique opportunity to look at early adoption of innovation in substance abuse treatment.
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Rogers (2003) has pointed to the importance of studying early adoption of innovation in
order to understand organizational characteristics that allow service providers to address
client needs.
The next chapter provides background on medication-assisted treatment and
possible barriers to adoption of this form of treatment. The third chapter on the
theoretical framework outlines neoinstitutional theory and the theory of institutional
logics, the organizing conceptual framework used in this research. The fourth chapter
reviews the literature describing organizational factors associated with the provision of
services in substance abuse treatment. The review highlights the concepts of
neoinstitutional theory and institutional logics, and will be used to generate general
hypotheses about how organizational forces shape service provision. The fifth chapter
provides an overview of the methods culminating in the hypotheses stated in terms of the
operationalized variables. The sixth chapter details findings from both the qualitative and
quantitative components of the study, respectively. Finally, an integrative discussion of
the results and implications for future research will be presented in chapter seven.
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Chapter 2
Background
The Organizational Field
Substance abuse treatment facilities in the U.S.
Since 1992, the Substance Abuse and Mental Health Services Administration
(SAMHSA) has been conducting an annual census of facilities providing treatment
services in the U.S.1 In the National Survey of Substance Abuse Treatment Services (NSSATS) SAMHSA collects data on the location, organizational and client characteristics
of treatment facilities and services throughout the 50 States, the District of Columbia, and
other U.S. jurisdictions (e.g. Guam, Puerto Rico and US Territories).
According to the latest report available, a little less than 1.2 million persons per
year are treated in 13,339 substance abuse treatment facilities across the U.S. (see figure
2.1. below). These include program level, clinic level and multi-site level facilities, but
not jail or prison-based programs. All numbers in this section are based on a 91.4 percent
survey response rate of the 2010 N-SSATS (SAMHSA, 2011b).
The majority of facilities surveyed (58%) were private non-profit, a number that
has remained relatively constant in recent years. Private for-profit facilities represented
30 percent of all facilities in 2010, a five percent increase since 2003. Over 80 percent of
all facilities offered outpatient care. These facilities served 90% of all clients. Nonhospital based residential treatment was offered by nearly 26 percent of facilities, but
received by only 9 percent of clients. Inpatient hospital treatment was offered by 6
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percent of facilities, but accounted for only 1 percent of client care. Nine percent of all
facilities offered opioid replacement therapy (i.e. methadone maintenance,
buprenorphine/naloxone) between 2006-2010. However, these facilities served nearly a
quarter of all clients. Sixty percent of facilities reported receiving Federal, State of local
government funds, and 95 percent of all facilities reported that they were licensed,
certified, or accredited by one or more agency or organization (SAMHSA, 2011b).
Though the question was not asked in the latest survey, in a previous survey almost half
of the facilities reported contracts with managed care organizations (SAMHSA, 2008).

Figure 2.1. Location of treatment facilities in the U.S. on March 31st, 2008
(SAMHSA, 2008)
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Over 90 percent of all facilities provided screening for substance abuse for
assessment and pre treatment services. Ninety percent provided comprehensive substance
abuse assessment or diagnosis; nearly 67% of facilities screened for mental health
disorders, and only 20% reported providing intermediate services when immediate
admission was not possible. The prevailing clinical/therapeutic approaches, reported to be
used always or often, were substance abuse counseling (95%) and relapse prevention
(85%). Additional approaches reported to be used always, often or at least sometimes
were cognitive-behavioral therapy (92%), motivational interviewing (87%), anger
management (84%), brief intervention (82%), 12-step (80%), trauma-related counseling
(67%), and contingency management/motivational incentives (58%) (SAMHSA, 2011b).
Over eighty percent of facilities reported that they offered programs for needs of
specific client types. Almost two fifths of the facilities offered services specifically
tailored for clients with co-occurring mental health and substance abuse disorders.
Roughly 30 percent of programs reported that they provided services for adult women,
adolescents and DUI/DWI offenders each. Twenty-seven percent of facilities offered
services for criminal justice clients and 25 percent offered specialty services for adult
men. Among the less frequently offered were programs for pregnant or postpartum
women (13%), persons with HIV or AIDS (9%), seniors or older adults (7%), and
lesbian, gay, bisexual or transgender (LGBT) clients (6%) (SAMHSA, 2011b).
Finally, while some form of pharmacotherapy was offered by nearly 50% of
facilities, most offered only medication for psychiatric disorders (34.6%). A little over
11% offered methadone, while 18.4% offered buprenorphine/naloxone in 2010
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(SAMHSA, 2011b). While the percentage of programs offering methadone has remained
relatively steady since 2002 (the year in which buprenorphine/naloxone was approved for
use), the percentage of programs adopting buprenorphine/naloxone has been steadily
increasing.

Medication-assisted treatment for opioid dependence
Methadone and buprenorphine/naloxone are the two recommended
pharmacotherapies for the treatment of opioid dependence (VA, 2009; Soyka, Kranzler,
van den Brink, Krystal, Muller, & Kasper, 2011). They are considered the ‘gold standard’
for treatment, as numerous clinical trials have demonstrated their effectiveness (Oliva et
al., 2011). Before describing these two forms of treatment and summarizing the evidence
of their effectiveness, a brief overview of opiates and opioid dependence is provided.
Opiates and opioid dependence.
Opiates, including heroin, morphine and other prescription painkillers (such as
OxyContin, Vicodin, and Fentanyl) are psychoactive substances that act on receptors in
the brain, which also interact with endorphins. Endorphins are important in regulating
pain and emotion. Thus, while prescribed use of certain painkillers can be highly
beneficial, opiates can be highly addictive because of their euphorigenic properties
(Brown, 2004; NIDA, 2006). This is particularly true for heroin, developed from opium
(poppy) originally as a cough suppressant in 1985 (Brown, 2004).
Opioid dependence is a chronic relapsing condition characterized by compulsive
self-administration of opioids that persists despite adverse consequences (Brown, 2004).
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The ICD-10 defines dependence as “a cluster of physiological, behavioral, and cognitive
phenomena in which the use of a substance or a class of substances takes on a much
higher priority for a given individual than other behaviors that once had greater value.”
(World Health Organization, 1992). According to the ICD-10, drug dependence
manifests in compulsive substance use despite evidence of harm due to use, the presence
of characteristic withdrawal phenomena upon discontinuation or drastic reduction of use,
development of tolerance to the effects of the substance, and dysfunction in other life
areas due to use and/or preoccupation with use (Brown, 2004).
Similarly, the DSM-IV (2004) defines dependence as ‘a maladaptive pattern of
use, leading to clinically significant impairment or distress, as manifested by 3 or more
diagnostic symptoms, occurring at any time in the same 12-month period. Symptoms can
include: tolerance, as defined by either the need for markedly increased amounts of
substance to achieve intoxication or desired effect or markedly diminished effect with
continued use of the same amount of substance; withdrawal, as manifested by either the
characteristic withdrawal syndrome for opiates (3 of: dysphoric mood, nausea or
vomiting, muscle aches, lacrimation or rhinorrhea, diarrhea, yawning, fever, insomnia,
gooseflesh, sweating) or the same (or a closely related) substance is taken to relieve or
avoid withdrawal symptoms; substance taken in larger amounts over a longer time period
than intended; persistent desire or repeated unsuccessful attempt to quit; much
time/activity to obtain, use, recover; important social, occupational, or recreational
activities are given up or reduced, and; continued use despite knowledge of adverse
consequences (American Psychiatric Association, 1994).
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According to the National Survey on Drug Use and Health, an estimated 3.7
million people had used heroin at some time in their lives (NSDUH, 2004), and 200,000
of them reported using it within the month preceding the survey (SAMHSA, 2011a). An
estimated 314,000 Americans used heroin in the past year, and the group that represented
the highest number of those users were 26 or older. In 2003, over 55 percent of past year
heroin users were classified with dependence on or abuse of heroin, and an estimated
280,000 persons received treatment for heroin abuse (NSDUH, 2004). Heroin use,
particularly when injected, raises major public health concerns. There are significant and
costly medical illnesses heroin dependence, such as HIV, hepatitis C and other infectious
diseases. The social and economic costs due to associated crime and poverty exceed those
of most other drugs (Mark, Woody, Juday, & Kleber, 2001). In addition, 2 million
persons reported initial use of nonmedical painkillers with almost the same number of
persons classified as dependent on or abusing painkillers [NSDUH, 2011].

Methadone.
Worldwide, methadone is the most widely studied and accepted form of
medication therapy for opiate addicts (Mattick, Kimber, Breen, & Davoli, 2008; NIH
Consensus Panel 1998; Farrell et al. 1994, Marsch, 1998). Developed in the 1940s to treat
pain, methadone is an orally administered full mu-opioid (morphine-like) agonist that
reduces the withdrawal symptoms of and represses cravings without bringing about the
euphoric feeling associated with the use of illicit opioids (Centers for Disease Control
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and Prevention, 2002; Donny, Walsh, Bigelow, Eissenberg, & Stitzer, 2002, Marsch,
1998).
Methadone, administered daily, is regulated and offered only in licensed specialty
treatment programs designed to offer treatment for opiate addicts. For decades,
Methadone maintenance has been shown to reduce the frequency of opiate use
(Langendam, van Brussel, Coutinho, & van Ameijden, 2001; Ling, 1976; Mattick et al.,
2008), mortality (Ward, Malrick, & Hall, 1994; Langendam et al., 2001), and
transmission of HIV (Ball, Lange, Myers, & Friedman, 1988; Des Jarlais et al., 1996). A
recent meta-analysis of 11 clinical trials summarized the effectiveness of methadone
maintenance for the treatment of heroin addiction compared to treatments that did not
involve replacement therapy. The authors concluded that methadone was significantly
more effective than non-medication treatments in retaining patients in treatment and in
the suppression of heroin use as measured by self report and urine/hair analysis, but not
statistically different in criminal activity or mortality (Mattick et al., 2008).

Buprenorphine/naloxone.
Buprenorphine/naloxone (marketed as Subutex® and Suboxone®) is a partial muopioid agonist that acts on the same receptors as heroin and morphine, relieving drug
cravings without producing the same intense "high" or dangerous side effects (NIDA,
2006). Approved by the U.S. Food and Drug Administration in October 2002,
buprenorphine/naloxone can be offered through community office-based settings (Amass
et al., 2004; Brown, 2004; Ling et al., 2009; Mattick et al, 2008). Furthermore,
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buprenorphine/naloxone treatment was implemented successfully in both inpatient and
outpatient treatment settings (Amass et al, 2004). Consequently, buprenorphine/naloxone
may present an appealing alternative for treatment providers and organizations that wish
to expand their services but are unwilling or unable (for instance due to regulatory issues)
to obtain a license for the use of methadone. To facilitate the dissemination of
buprenorphine/naloxone, NIDA and SAMHSA's have recently developed and published
training materials for interested providers (Ducharme, Knudsen, Roman, & Johnson,
2007).
Numerous clinical trials have been conducted to examine the effectiveness of
buprenorphine/naloxone (Ling &Wesson, 2003). In a recent meta-analysis of 24 clinical
trials summarized the effectiveness of buprenorphine/naloxone for the treatment of heroin
addiction compared to treatments that did not involve replacement therapy and compared
to methadone maintenance. The authors found that buprenorphine/naloxone was
significantly more effective than non-medication treatments in retaining patients in
treatment and in the suppression of heroin use when provided in medium or high doses as
measured by self-report and urine/hair analysis. They also found that
buprenorphine/naloxone was less effective than methadone prescribed at adequate dose
levels (Mattick et al., 2008).
Barriers to adoption.
Oliva and colleagues (2011) recognize that various pharmacotherapies, though
considered to have a strong evidence-base, are largely underutilized in substance abuse
treatment settings. Utilizing a multi-level framework, they describe in detail some of the
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main system, provider and patient-level barriers to the adoption and use of
pharmacoptherapies (Oliva, Maisel, Gordon, & Harris, 2011).
System-level barriers include Government and insurance policies that impact the
availability and cost of services, program characteristics (e.g., treatment philosophy) and
practices (e.g., suboptimal dosing), lack of pharmaceutical industry support compared
with other psychiatric medications, and logistical issues such as lack of access to
prescribing physicians, limited clinical and administrative support, cost concerns, issues
with coordinating care, difficulties obtaining medications at local pharmacies, and the
burden of laboratory testing. Provider-level barriers to the adoption of medicationassisted treatment include informational barriers (e.g. inadequate training of lack of
knowledge), provider perceptions and concerns regarding effectiveness and demand and
their own ability to utilize these medications appropriately. In addition to cost and access,
an important patient-level barrier is lack of information. Considerably less attention has
been paid to research examining patient perspectives, knowledge, and attitudes regarding
medication therapy, a possible avenue for future research (Oliva et al., 2011; see also
McLellan, Lewis, O’Brien, & Kleber, 2000).
Though the authors do not utilize a theoretical framework to organize their review
of the literature pertaining to barriers associated with the use of pharmacotherapies, their
analysis supports the use of a multi-level approach when studying adoption and
utilization of practices. The conceptual framework of neoinstitutional theory and
institutional logics detailed in the next chapter can be used to examine how various
organizational processes and practices are formed and shaped. This study proposes to
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apply and test the framework to study the provision of pharmacotherapies in substance
abuse treatment organizations in the U.S. Studies from the last couple of decades have
been concerned with various forces that may explain or predict the provision of services
in this organizational field. The following chapter also reviews the literature on how
organizational practices are formed and shaped in the field of substance abuse treatment
leading to research questions and hypotheses.
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Chapter 3
Conceptual Framework
In an attempt to understand why organizations are so similar to one another, and
why the adoption of new items and practices is often slow, neoinstitutional theorists
argue that organizational practices are structured by processes originating in an
organization’s institutional field (DiMaggio & Powell, 1983; Fligstein, 1990; Meyer &
Rowan, 1977; Zucker, 1988). Organizational fields refer to a group of organizations that
“constitute a recognized area of institutional life: key suppliers, resource and product
consumers, regulatory agencies, and other organizations that produce similar services or
products” (DiMaggio & Powell, 1983, p.148). Interactions among organizations within a
particular field result in the emergence of clear interorganizational patterns, and the
development of an understanding regarding the nature of their shared environment
(DiMaggio & Powell, 1983).

Neoinstitutional theory and forces influencing organization
Neoinstitutional theory highlights the manner in which organizations become
more like other organizations in their field as a result of external pressures exerted on
them (DiMaggio & Powell, 1983; Fligstein, 1990; Meyer & Rowan, 1977; Zucker, 1988).
This homogenization, or isomorphism as it is more widely referred to, is a ‘constraining
process that forces one unit in a population to resemble other units that face the same set
of environmental conditions’ (DiMaggio & Powell, 1983, p.149). Neoinstitutional theory

	
  

16	
  

	
  
posits that individual actors are unable to visualize alternatives and thus they diffuse
shared beliefs, or institutional myths, across organizations (Fligstein, 2001).
DiMaggio and Powell (1983) describe three forms of institutional isomorphism: coercive,
mimetic and normative.
Coercive isomorphism, results from pressure exerted on organizations by other
organizations on which they are dependent for funding or legitimacy. This pressure can
be formal (e.g. government mandate, laws, regulatory agencies) or informal (i.e. societal
and cultural expectations of the environment).
Mimetic isomorphism results when organizations mimic other organizations that
they view as successful in order to survive or gain legitimacy. By modeling others,
organizations sometimes adopt innovations, without consideration of their effectiveness
or efficiency.
Normative isomorphism results from the pressures exerted by the norms that
emerge in an organizational field through professionalization and standardization.
Organizations find themselves steered to adopt prevalent norms, standards and practices
in order to find legitimacy in their organizational field.
Institutional isomorphism is hypothesized to progress even in the absence of any
indication that the new models, practices or organizational structures being adopted are
effective or efficient. Often is the case that the structure of an organization is a
manifestation of the myths of the institutional environment, which pays little attention to
what should be accomplished (Meyer & Rowan, 1973). In other words, in these cases
efficiency is not the main priority (see also Thornton & Ocasio, 1999, 2008; Tolbert &
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Zucker, 1983). DiMaggio and Powell (1983) suggested that if effectiveness is enhanced
in a modeling organization (an organization that mimics others in its field), it is often a
result of the organization being rewarded for its likeness to other organizations in its
field, thereby gaining legitimacy, prestige and funding opportunities. Thus, an isomorphic
organization is not necessarily more efficient than its less conforming peer.
While neoinstitutional theory provides an important framework for examining
organizational change and stability, it has often been critiqued for being overly
deterministic, unidirectional (i.e. top-down) and for ignoring the role of agency
(discussed below) in processes of organizational change (Cooney, 2007; Fligstein, 2001;
Scott, 2008). Giddens (1984) argued that neoinstitutional theory treats individual actors
as passive and powerless in the face of institutional forces exerted on them (see also
Fligstein, 2001).
Rational choice neoinstitutionalism emphasizes a fixed set of rules that allow for
rational decision making processes among individual actors while sociological
neoinstitutionalism emphasizes uncertainty and isomorphic processes that are led by
professionals and governments. Neither form of neoinstitutionalism adequately considers
the issue of agency - individuals’ power to act independently, to make choices, to
mobilize resources in order to impact social structures in the face of prevalent
institutional logics, rules and myths (Fligstein, 2001).
A related issue, often neglected by neoinstitutionalists, is power.
Neoinstitutionalism focuses on actors as disseminators of myths and rules, suggesting
they have no real motive for taking action. Thus, neoinstitutionalism by itself cannot
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answer questions pertaining to how and why new institutions emerge, which actors act,
why they do so and what meanings exist or do not exist (Fligstein, 2001). Institutional
logics, discussed in more detail the following section, extend neoinstitutional theory and
provide a framework for better understanding conflicting institutional environments.
Institutional logics
Institutional logics expands neoinstitutional theory’s focus on isomorphic
institutional processes by incorporating the contradictory institutional forces at play in an
organizational field. Institutional logics can be thought about as ‘taken-for-granted sets of
understandings about what kinds of things exist, what kinds of practices might be
deployed and what kinds of rationales could be offered to legitimate actions taken’ (Mohr
& Guerra-Pearson, 2007). Further, institutional logics highlights the manner in which
organizational practices are shaped by organizational actors, who in turn, are responding
to their social locations in organization and within other networks (Thornton & Ocasio,
2008). These multilevel environments both constrain behavior and enable agency
(Friedland and Alford, 1991; Jackall, 1988; Thornton & Ocasio, 1999). In other words,
the underlying logics of institutions both structures heterogeneity and homogeneity, as
well as shape innovation and change in organizations (Thornton & Ocasio, 2008).
Institutional logics were first conceptualized by Alford and Friedland (1985) to
explain inconsistent belief systems and practices in institutions (Friedland & Alford,
1991). As mentioned above, institutional logics are similar to neoinstitutional theory in
the emphasis on how organizational structure is shaped by institutional forces. However,
the focus is not on isomorphism and conformity, but on how competing logics originating
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in diverse environments shape organizational behavior. Institutional logics shape rational
behavior of individuals while these organizational actors change the institutional logics
and shape the organizational structure (Thornton & Ocasio, 2008).
Individual values, beliefs and identities are embedded within the dominant
institutional logics, while change and innovation are the result of interactions between
agency and structure. Organizational form and adoption of innovations are thus explained
by variation in prevailing institutional logics, rather than by isomorphic processes and
conformity, thereby allowing for consideration of stability as well as heterogeneity,
conflict, and change (Friedland & Alford, 1991; Jackell, 1988; Thornton & Ocasio, 1999,
2008). Thus, the idea of institutional logics extends neoinstitutional theory by pointing
out that organizational practices and structure are explained by different, often conflicting
institutional environments, rather than by isomorphism and conformity.
Three concepts enunciated by institutional logics theorists have special relevance
to the field of innovative service provision in substance use treatment:
Competing organizational identities: Scholars have argued that organizational
identities, and associated ideologies are constituted by sets of social codes, rules, rituals
and interpretive schema that an organization is expected to possess (Hannan, Polos &
Carroll, 2005; Polos, Hanan & Carroll, 2002) and utilize to define its purpose (meaningmaking). Organizational actors become the carriers of organizational identities (Hsu &
Hanan, 2005). It is often the case that different sets of organizational actors adhere to
different identities. Hsu and Hanan (2005) note that within organizations, ideological
differences may exist between top managers and entry-level workers, permanent and
	
  

20	
  

	
  
temporary employees, and female and male workers, whereas in the institutional field,
differences may exist between extra-organizational actors such as regulators, critics,
industry analysts, consumers and clients, and potential employees.
Differences in organizational identities can trigger change and innovation.
Examining changes in the U.S. brewing industry, Carroll and Swaminathan (2000) note
that consolidation between local brewing firms with mass-produced industrial brewing
practices produced two unique forms of brewing that were in opposition to national
breweries: microbrewery and brewpubs that prioritized small-scale handcrafted methods
of beer production. Similarly, food-cooperatives have incorporated innovative and
competing identities (McEvily & Ingram, 2003). Food co-ops that had adopted the
practices of large supermarkets by creating hierarchical organizational structures, went
back to cooperative structures, when for-profit chains began entering the natural food
market niche. Clashes in identities between the two types of organizations forced smaller
food-co-ops to distinguish themselves by adopting innovative horizontal and democratic
organizational bureaucracies. This process of adoption of new ways due to identity
competition is enunciated in a study on French gastronomy where Rao, Monin and
Durand (2003) document the way in which the nouvelle cuisine movement led elite chefs
schooled in classical cuisine to adopt new approaches, identities and technologies. In this
case, adoption was a result of collective identity processes whereby organizational actors
plugged into the interpretive schema (or movement frame) of the nouvelle cuisine
movement in order to change old institutional identities.
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The salience of milieus: Drawing on Bourdieu’s (1988) notion of habitus to
describe the extra-organizational institutional field which structures organizational
behaviors, Everett (2002) notes that organizational actors belong to networks and milieus
which are marked by particular cultural practices and beliefs. The cultural ethos attached
to these milieus shapes actors’ orientations and have the potential to influence their
organizational behaviors and choices. Ozbilgin & Tatli (2005) emphasize the importance
of Bourdieu’s formulation of social and cultural capital in understanding the way
organizational actors draw on various repertoires of capital in making decisions about
organizational practices. They note that social relationships outside the organization (that
help to build social capital), as well as the kinds of symbolic, ideological and affective
processes that are nurtured (thus developing cultural capital) in these external milieus, are
important influencers of behavior in organizations. In explaining the manner in which
nouvelle cuisine redefined French culinary traditions in France in the 1970s, Rao &
colleagues (2003) for instance, emphasize the manner in which acclaimed French chefs
were influenced by the cultural networks they were embedded in at the time, many of
which were instrumental in critiquing the status quo in other fields like the government,
theatre, the arts and the humanities. Similarly, examining the way welfare workers
negotiated rigid welfare-to-work organizational rules at welfare agencies, Cooney (2007)
found that their personal connections to families and friends who were finding it hard to
deal with the lack of jobs at the time, made them resist an organizational ethos that
blamed welfare recipients for being unemployed.
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Embedded agency: Institutional logic scholars note that organizational actors and
organizations, embedded as they are in organizations and extra-organizational
institutional fields, are shaped by organizational and institutional processes, but
simultaneously have the ability to shape these processes themselves (Battilana, 2006;
Friedland & Alford, 1991; Seo & Creed, 2002; Thornton & Ocasio, 2008). Organizations
and institutions thus both constrain agency, but are also subject to it (Giddens, 1984;
Sewell, 1992). Legitimacy, valence, power and leadership characterize the modes through
which embedded actors achieve change and re-shape the structural processes that seek to
shape them (Thornton & Ocasio, 2008).
Summary
Institutional logics as a theory considers the processes of the interplay between
multiple ideal types present in the organizational field, and of the strategizing that occurs
on the part of agency. While many neo-institutional theorists also discuss the multiple
levels of institutions present, institutional logic theorists combine this discussion with a
discussion of the role of agency embedded within organizations.
Thornton and Ocasio (2008), in discussing common misconceptions regarding
institutional logics, point out that ‘ideal types are not a description of what happens in an
organizational field. Ideal types are formal analytical models by which to compare
empirical observations across institutions’ (p.119). They also point out that many studies
consider ideal types and develop typologies of those ideal types within an organizational
field, but fail to tie their analysis back to the institutional orders of the inter-institutional
system.
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Thus, in addition to considering the various logics that are at play in an
organizational field, we must focus on the process of strategizing on the part of agency.
As stated by Thornton and Ocasio (2008), ‘institutional logics, do not emerge from
institutional fields – they are logically instantiated and enacted in organizational fields
and in other places such as markets, industries and organizations’ (p.119). While
considering ideal types of institutional forces in a particular field is important, the
contribution of institutional logics is the process of local enactment of picking a
particular logic over another, mixing logics, and bringing in personal logics from various
networks.
In conclusion, the theory of institutional logics suggests that in order to
paint a more detailed picture of how organizational practices are formed and shaped in a
particular organizational field multiple factors and the interaction between them ought to
be considered. Specifically, consideration should be given to the role of agency and the
various networks they are embedded in, ideal types of institutionalisms present in the
field and the (sometimes conflicting) logics related to them, and structural factors such as
market forces, or internal and external organizational characteristics.
This study aims to explore the role these factors play in the adoption of
medication-assisted treatment within the organizational field of substance abuse
treatment. To this end, the following section provides an integrated review of previous
organizational and institutional literature in the field.
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Chapter 4
Literature Review
Though the conceptual model of institutional logics detailed in the previous
chapter can be used to examine how various organizational processes and practices are
formed and shaped, this study proposes to apply and test the framework to study the
adoption of medication-assisted treatment in substance abuse treatment organizations in
the U.S. Studies from the last couple of decades have been concerned with various forces
that may explain or predict the adoption of new practices in this organizational field. The
following section reviews the literature on how organizational practices are formed and
shaped in the field of substance abuse treatment leading to research questions and
hypotheses.

Neoinstitutionalism, Institutional Logics and Substance Abuse Treatment
Researchers have pointed to a substantial gap between the practices that research
has shown to be effective and the practices that are utilized in the field of substance abuse
treatment. In an effort to understand this gap, scholars have focused their attention on the
role of institutional and organizational-level factors in the provision and utilization of
services and in shaping organizational practices. They have pointed to the importance of
studying substance abuse treatment at these levels as a means to inform decision makers
and improve the quality of care (i.e. D’Aunno, 2006; Durkin, 2002; Hasenfeld, 2008).
Substance abuse treatment organizations have often been criticized for their slow
adoption of new practices (Knudsen & Roman, 2004; Lamb et al., 1998; Roman &
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Johnson, 2002; Sloboda & Schildhaus, 2002), with some scholars suggesting that various
organizational characteristics play a significant role in explaining the adoption and
implementation of new practices and technologies (e.g. D’Aunno, 2006; D’Aunno et al.,
1991; Guerrero, 2009; Roman & Johnson, 2002; Simpson & Flynn, 2007). Of particular
importance to adoption of innovations in substance abuse treatment are organizations’
institutional environments, such as funding sources, licensing and accreditation agencies,
and ownership, that may demand (or hinder) the adoption of new practices (Baum &
Oliver, 1992; D’Aunno, 2006; Ghose, 2006, 2008; Hasenfeld, 1992).
While Simpson and Flynn focused mostly on organizational factors that are
considered to be internal to the organization (such as motivation, institutional resources
and staff attributes), D’Aunno (2006) emphasized the role of external institutional
demands such as ownership, size of the organization, accreditation and managed care
arrangements. Institutional theory scholars have described an interlocking system of
institutional forces that shape organizational practices. The conceptual framework
described by neoinstitutional theory and institutional logics is useful in understanding the
organizational practices of substance abuse treatment facilities

Institutional Forces: Coercive and Normative
Both coercive, as well as normative forces influence service provision in
substance abuse treatment programs. Coercive forces are associated with the control
exerted by funding, licensing and parental organizational sources. Normative forces in
substance abuse treatment are characterized by managerial attitudes that shape the norms
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associated with service provision, as well as client characteristics that shape the standards
of care associated with certain types of client profiles.
Coercive institutional forces
Funding and managed care arrangements: Treatment services rely mostly on
public funding and insurance payments (Durkin, 2002; SAMHSA, 2011b), which come
with ties (D’Aunno, 2006). Licensing and professional accreditation agencies can also
influence services provided (D’Aunno, 2006), as can managed care firms (Durkin, 2002;
Lemak & Alexander, 2001; Sosin, 2002). The growth of managed care as a source of
funding in substance abuse treatment has been extensive in recent years (Alexander,
Lemak & Campbell, 2003). Scholars have found that managed care regulation is
negatively correlated with treatment intensity (Lemak & Alexander, 2001) and the
number of services provided (Corcoran & Vandiver, 1996; Gold, Hurley, Lake, Ensor &
Berenson, 1995; Olmstead, White & Sindelar, 2004), limits autonomy of the provider
(Alexander & Lemak, 1997; Mechanic, Schlesinger, & McAlpine, 1995; Schlesinger,
Dorward, & Epstein, 1996; Schwartz & Wetzler, 1998), does not increase technical
efficiency in service provision (Alexander, Wheeler, Nahra & Lemak, 1998) and
increases relapse rates (Sosin, 2005). In their study of early adoption of
buprenorphine/naloxone, Knudsen and colleagues (Knudsen, Ducharme & Roman, 2006)
found that private centers were significantly more likely than public centers to report
current use of buprenorphine/naloxone.
Licensing: Ninety-five percent of substance abuse treatment programs in the U.S.
reported being licensed, certified or accredited by at least one agency (81% by the their
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state), 47% reported having agreements or contract with managed care firms, and 60%
receive either federal, state or local government funding (SAMHSA, 2008). These high
percentages suggest that demands made by these agencies are influential in determining
services offered in substance abuse treatment programs. Research has shown this to be
the case with mental health services in substance abuse treatment (Durkin, 2002), and in
HIV prevention (D’Aunno et al., 1999). Facilities accredited by the Joint Commission on
the Accreditation of Healthcare Organizations (JCAHO) were more likely to provide
primary care and mental health services (Friedmann, Alexander & D’Aunno, 1999;
D’Aunno, 2006), physical exams and routine medical care (Durkin, 2002), use
antidepressants (Knudsen, Ducharme, & Roman, 2007b) and be early adopters of
buprenorphine/naloxone (Knudsen et al, 2006). National and state licensing agencies are
likely to have a broader picture of addiction, HIV and the importance of reducing HIV
rates among intravenous drug users (D’Aunno et al., 1999).
Parental organizational control: Scholars have argued that external agencies
influence organizations’ adoption of practices and policies, specifically agencies on
which the organization relies on for resources (Pfeffer & Salancik, 1978) and legitimacy
(D’Aunno, 2006; DiMaggio & Powell, 1983). Parent organizations, such as hospitals or
mental health centers are an important aspect of an organization’s external environment.
Research has shown that the type of parent organizations is an explanatory factor in the
provision of services (D’Aunno et al., 1991, 1999; Ghose, 2006) and outcome of
treatment (Ghose, 2008). D’Aunno and colleagues (1999) note that parent facilities tend
to provide more financial and resource support to substance abuse facilities that adopt
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methods, technologies and ideologies that are similar to their own. For instance, units
affiliated with hospitals were more likely to provide medical care, HIV testing and HIV
counseling services (D’Aunno, 2006; D’Aunno et al., 1999). Knudsen and colleagues
(2006) found that early adoption of buprenorphine/naloxone was also positively
associated with being located in a hospital setting.
The research suggests that coercive forces are at play in substance abuse treatment
facilities:
1a) I propose that centers that have state licensing, JCAHO or CARF
accreditation and a parent organization that is a medical facility will be
more likely to provide medication-assisted treatment and be early
adopters

of

new

medication-assisted

treatment

modalities

than

organizations who do not have state licensing, JCAHO or CARF
accreditation or parent organization that is a medical facility.
1b) Further, I propose that centers with a higher proportion of funding
derived from managed care and those who report greater impact by
managed care arrangements will be less likely to provide medicationassisted treatment and less likely to be early adopters of new medicationassisted treatment modalities than organizations with lower proportions of
funding derived from managed care and those who report less impact of
managed care arrangements.
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Normative institutional forces
Norms in a substance abuse treatment agency are established through managerial
attitudes and orientations as well as the kinds of clients an agency caters to.
Managerial attitudes: Managerial support for new practices is often crucial in
the adoption process (D’Aunno et al., 1991; Klein & Sorra, 1996). For instance, D’Aunno
and colleagues (1999) studied the adoption of HIV prevention practices in outpatient
substance abuse treatment units and found that adoption was more likely when managers
supported the efforts.
D’Aunno and colleagues stress the key role that institutional beliefs and norms
play in the adoption of new practices in substance abuse treatment organizations
(D’Aunno, 2006; D’Aunno et al., 1991; D’Aunno et al., 1999). Thus, adoption of
organizational practices is often shaped by values within the larger institutional
environment, rather than on efficiency (D’Aunno, 2006; Scott, 2008).
Rosenberg and Phillips (2003) studied attitudes towards harm reduction among
providers of substance abuse treatment in the U.S. They found that while 50% of
respondents (mostly persons in clinical and managerial positions) rated several forms of
harm reduction as somewhat or completely acceptable; the interventions themselves were
not widely available at their agencies. For instance, only 1% of agencies offered needle
exchange programs, 9% offered long-term methadone maintenance, and 23% and 38%
accepted non-abstinence as final and intermediate treatment goals, respectively. For most
forms of harm reduction included in the study, the main reason reported for lack of
availability was inconsistency with the agency’s philosophy, followed by lack of
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resources and funding. For non-abstinence treatment goals, the main reasons provided by
respondents were inconsistency with the agency’s philosophy, not wanting to send the
wrong message to clients, and belief that these goals are ineffective. Though the authors
collected some organizational level data, their study remained descriptive in nature, and
possible associations between the availability of harm reduction strategies and
characteristics of the agencies and staff were not explored.
Client Characteristics: Norms in the types of services offered are also
established by the types of clients being served by agencies. Hasenfeld (1992) notes that
clients comprise the “raw material” for human service agencies and often dictate the
types of treatment and service technologies adopted by the organization. Examining the
extent to which psychologists accept harm reduction practices based on characteristics of
their clients, Wryobeck and Rosenberg (2005) found that previous treatment attempts and
HIV status were positively associated with the acceptability of needle exchange among
psychologists, while other client characteristics, such as gender, race, employment status
and criminal history were not. The acceptability of short-term methadone was
significantly associated with client populations having a longer history of use, and with
more previous treatment episodes. In a sample of over 2,300 specialized substance abuse
treatment facilities in the U.S., Ghose (2006) found that higher proportions of clients
vulnerable to HIV infection were positively associated with the provision of specialized
substance abuse treatment to seropositive clients. Another study, found that higher
percentages of relapsers increased the likelihood a center will use naltrexone (Roman &
Johnson, 2002). Early adoption of buprenorphine/naloxone was found to be associated
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with the percentage of opiate-dependent clients (Knudsen et al., 2006). These findings
suggest that substance abuse treatment facilities’ orientation might be shaped by client
characteristics.
Taken together, these findings suggest that managerial attitudes and client
characteristics shape the normative environment with respect to treatment modality in a
substance abuse facility.
2a) Thus, I propose that centers whose managers are more positive
towards medication-assisted treatment will be more likely to provide them
and be early-adopters of new medication-assisted treatment modalities
than centers whose managers are less positive.
2b) I also propose that centers with higher proportions of clients with
more serious drug and drug-related problems (e.g. opiate users, relapsers,
dual-diagnosis) will be more likely to provide medication-assisted
treatment and be early adopters of new medication-assisted treatment
modalities than centers with lower proportions or these clients.

Institutional Logics
Several organizational factors that influence substance abuse treatment highlight
the manner in which institutional logics shape service provision. Specifically, service
provision is influenced by competing logics associated with different types of treatment
ideologies, the types of milieu that providers are embedded in, embedded agency as
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characterized by organizational age and size, as well as by characteristics of its leadership
and their support for provision of services.
Competing Identity logics
D’Aunno and colleagues (1991) explored the recent changes in the substance
abuse treatment system treatment by focusing on the merging of substance abuse and
mental health treatment sectors, each of which was dominated by a different identity, and
associated treatment ideology. The mental health orientation was embedded in a
psychological perspective with degreed professionals providing treatment, while the 12step orientation, based in an abstinence-only approach was implemented through
recovering (often non-degreed) counselors providing the majority of treatment. Each
ideology brought with it a set of underlying assumptions regarding the etiology of
addiction, as well as a different set of technologies. Treatment units operating in this
environment were thus subject to two beliefs systems, or sets of ideological logics, which
were often at odds. The mental health approach favored therapy and evidence-based
practices, while the abstinence approach relied on modeling and mentoring by those in
recovery, and attendance of 12-step recovery groups. Similarly, Ghose (2006) found that
a treatment program’s modality was a manifestation of its ideology and internal ethos:
methadone-maintenance programs that were partial to harm reduction methods were
more likely to offer specialized treatment services to seropositive clients.
D’Aunno and collogues (1991) studied ‘hybrid units’, treatment units that provide
substance abuse services alongside mental health services. While acknowledging that
each individual sector was dominated by a fairly distinct set of logics, they proposed that
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hybrid units borrow from both sets, which were often at odds. Hybrid units, or mental
health services that added a drug abuse component to their service, were exposed to new
practices and beliefs. This exposure led to pressures of gaining legitimacy in the drug
abuse sector on the one hand, but also being forced to adopt new, evidence-based
treatment practices in order to stay legitimate in the mental health field. The authors
proposed that hybrid units would incorporate practices consistent with both sets of
beliefs, practices that might be ‘structurally incompatible’ with each other. Furthermore,
they proposed that since organizations could not incorporate every new conflicting
practice, they would favor those that helped them achieve a minimum level of legitimacy
in the conflicting institutional environments. Consequently, they found that hybrid units
emphasized the hiring of professionals more than drug abuse treatment units and the
hiring of personnel in recovery more than mental health units. They argue that the
inconsistent practices exhibited by hybrid units were a byproduct of the addition of
abstinence as a treatment goal; that these units were not abandoning traditional mental
health practices, but rather, mixing them with new practices, a phenomenon they termed
‘partial adaptation’.
The literature in this section suggests that competing identity logics influence the
provision of services. Following D’Aunno’s lead, I propose that institutional identities
(and associated ideological logics) as measured by the proportion of counselors in
recovery and degreed counselors, and by centers’ emphasis on 12-step and medical
models shape a facility’s decision to provide services.
3a) I propose that centers with higher proportions of recovering
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counselors on staff with be less likely to offer medication-assisted
treatment and less likely to be early adopters of new medication-assisted
treatment modalities than centers with lower proportions of recovering
counselors on staff.
3b) Further, I propose that centers with higher proportions of degreed
staff will be more likely to offer medication-assisted treatment and be
early adopters of new medication-assisted treatment modalities than
centers with lower proportions of degreed staff.
3c) I also propose that centers with stronger emphasis on 12-step
approaches will be less likely to offer medication-assisted treatment and
less likely to be early adopters of new medication-assisted treatment
modalities than centers with lower emphasis on 12-step approaches, and,
3d) that centers with a higher emphasis on the medical model will be more
likely to offer medication-assisted treatment and be early adopters of new
medication-assisted treatment modalities than centers with lower
emphasis on the medical model.

The salience of provider milieus
While institutional logics emphasize the salience of habitus and external
networks, scholars of substance abuse treatment facilities for the most part, have not
explored the way the external habitus influences organizational processes. There is
however, some evidence to suggest that it may play a crucial role in influencing
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organizational decisions. D’Aunno and colleagues (1999) for instance, found that the
more time managers spent in research conferences or professional meetings, the more
likely they were to be familiar with new practices (like incorporating outreach services
for clients) and support their adoption. Similarly, summarizing extra-organizational
factors that influence service provision, D’Aunno (2006) notes that units whose directors
were linked to external professional networks were more likely to provide HIV
prevention, have collaborative relationships with other agencies and survive over time.
Knudsen and colleagues (Knudsen, Abraham, Johnson, & Roman, 2009) linked the
adoption of buprenorphine/naloxone to involvement in a buprenorphine/naloxone
protocol.
I propose that milieus that support evidence-based practices will encourage
managers to incorporate medication-assisted treatment. However, organizational actors
are also connected to another important milieu consisting of persons in recovery and
treatment alumni who have completed the program. This is especially true for those
providers who are recovering themselves and are connected to those in recovery. Given
the abstinence-based ideologies that people in recovery tend to adhere to (D’Aunno et al.,
1999) I propose that these milieus would nurture a resistance to medication-assisted
treatment.
4a) Therefore, I propose that centers with stronger connections to
substance abuse treatment research networks will be more likely to offer
medication-assisted treatment and be early adopters of new medicationassisted treatment modalities..
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4b) I also propose that centers with stronger connections to 12-step
recovery alumni networks will be less likely to offer medication-assisted
treatment and less likely to be early adopters of new medication-assisted
treatment modalities..

Embedded agency
Institutional logic scholars (Thornton & Ocasio, 2008) call attention to agency on
the part of organizations and organizational actors, that is sparked by being embedded in
institutional fields and organizational structures. While being entrenched in these
structures can result in normative organizational behavior, it can also lead to the ability to
make changes because of the power that is associated with familiarity with the field, and
credibility within it. The length of tenure of both facility and managers, as well as the size
of a facility measure the level of embeddedness and credibility within the treatment field.
Ghose (2006) found that size of agency (the number of clients served) was
positively associated with the provision of specialized substance abuse treatment to
seropositive clients. Another study found that size was positively associated with the
early adoption of buprenorphine/naloxone (Knudsen et al., 2006). In their study on
adoption and implementation of a new treatment technology, naltrexone (a drug that
reduces the rewarding aspects of drug use) in privately funded substance abuse treatment
centers in the U.S., Roman and Johnson (2002) found that adoption was positively
associated with the age of the treatment program. Older centers were more likely to adopt
naltrexone. Moreover, the tenure of managers in the field was also positively associated
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with offering naltrexone. D’Aunno et al. (1999) also found that larger mental healthsubstance use hybrid facilities were more likely than smaller facilities of the same kind to
depart from an exclusively abstinence-based model. They concluded that prevailing
mental health practices were more institutionalized in larger organizations, thus allowing
them to resist the abstinence-only treatment modality that accompanied mergers with
substance abuse treatment facilities.
The literature in this section suggests that embeddedness of actors in an
organization or an organization in an organizational field can at times allow actors and
organizations to innovate, buck prevailing trends and instigate change.
5a) Therefore, I propose that centers whose managers are more embedded
in an organization (as indicated by the length of their tenure) will be more
likely to offer medication-assisted treatment and be early adopters of new
medication-assisted treatment modalities than centers whose managers
are less embedded in an organization.
5b) I also propose that centers that are more embedded within their
organizational field (as indicated by their size and age) will be more likely
to offer medication-assisted treatment and be early adopters of new
medication-assisted treatment modalities..
5c) Finally, I propose embeddedness will interact with the correlates
described in the previous sections to influence the provision of
medication-assisted treatment to a greater degree.
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Summary of proposals emerging from the literature review
The literature review indicates that the provision of medication-assisted treatment
services being provided at a treatment facility is shaped by neoinstitutional forces, which
are coercive and normative, as well as by institutional logics processes like competing
ideologies, the salience of provider milieus and embedded agency.
Neoinstitutional forces
Hypothesis 1a (coercive): I propose that centers that have state licensing, JCAHO
or CARF accreditation and a parent organization that is a medical facility will be more
likely to provide medication-assisted treatment and be early adopters of new medicationassisted treatment modalities than organizations who do not have state licensing, JCAHO
or CARF accreditation or parent organization that is a medical facility.
Hypothesis 1b (coercive): I propose that centers with a higher proportion of
funding derived from managed care and those who report greater impact by managed
care arrangements will be less likely to provide medication-assisted treatment and less
likely to be early adopters of new medication-assisted treatment modalities than
organizations with lower proportions of funding derived from managed care and those
who report less impact of managed care arrangements.
Hypothesis 2a (normative): I propose that centers whose managers are more
positive towards medication-assisted treatment will be more likely to provide them and be
early-adopters of new medication-assisted treatment modalities than centers whose
managers are less positive.
Hypothesis 2b (normative): I propose that centers with higher proportions of
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clients with more serious drug and drug-related problems (e.g. opiate users, relapsers,
dual-diagnosis) will be more likely to provide medication-assisted treatment and be early
adopters of new medication-assisted treatment modalities than centers with lower
proportions or these clients.
Institutional logics processes
Hypothesis 3a (competing identity logics): I propose that centers with higher
proportions of recovering counselors on staff with be less likely to offer medicationassisted treatment and less likely to be early adopters of new medication-assisted
treatment modalities than centers with lower proportions of recovering counselors on
staff.
Hypothesis 3b (competing identity logics): I propose that centers with higher
proportions of degreed staff will be more likely to offer medication-assisted treatment
and be early adopters of new medication-assisted treatment modalities than centers with
lower proportions of degreed staff.
Hypothesis 3c (competing identity logics): I propose that centers with stronger
emphasis on 12-step approaches will be less likely to offer medication-assisted treatment
and be early adopters of new medication-assisted treatment modalities than centers with
lower emphasis on 12-step approaches.
Hypothesis 3d (competing identity logics): I propose that centers with a higher
emphasis on the medical model will be more likely to offer medication-assisted treatment
and be early adopters of new medication-assisted treatment modalities than centers with
lower emphasis on the medical model.
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Hypothesis 4a (salience of milieus): I propose that centers with stronger
connections to substance abuse treatment research networks will be more likely to offer
medication-assisted treatment and be early adopters of new medication-assisted
treatment modalities..
Hypothesis 4b (salience of milieus): I propose that centers with stronger
connections to 12-step recovery alumni networks will be less likely to offer medicationassisted treatment and less likely to be early adopters of new medication-assisted
treatment modalities.
Hypothesis 5a (embedded agency): I propose that centers whose managers are
more embedded in an organization (as indicated by the length of their tenure) will be
more likely to offer medication-assisted treatment and be early adopters of new
medication-assisted treatment modalities than centers whose managers are less
embedded in an organization.
Hypothesis 5b (embedded agency): I propose that centers that are more
embedded within their organizational field (as indicated by their size and age) will be
more likely to offer medication-assisted treatment and be early adopters of new
medication-assisted treatment modalities.
Hypothesis 5c (embedded agency): I propose embeddedness will interact with the
correlates described in the previous sections to influence the provision of medicationassisted treatment to a greater degree.
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Gaps and Limitations of Current Research
The studies described above are useful in identifying many predictors crucial to
the adoption of new practices, yet several gaps can be identified. Many of the studies,
with the notable exception of D’Aunno and colleagues do not attempt to organize their
hypotheses based on a theoretical framework. Furthermore, most studies reviewed
explore only organizational and/or institutional level factors, and tend to underplay the
possible role of agency in the adoption of practices. For instance, D’Aunno and
colleagues (1991) discuss how strong evidence or emotional and ideological arguments in
favor a particular practice may tempt managers (individuals) and organizations to
abandon one practice for another, hinting that agency might has a role in organizational
processes. However, they do not examine the unique role of agency or the strategizing
that occurs. This study addresses this issue by using the more comprehensive framework
of institutional logics to explore technological adoption.
Qualitative studies exploring possible individual-level factors pertinent to the
adoption of new practices in substance abuse treatment are rare. As a result, discussion of
the unique as well as combined effects of these various levels of analysis is scarce, and
discussion of the processes that shape organizational practices is missing. This study will
employs qualitative methods to examine the various institutional forces in the field of
substance abuse treatment, and to explore the logics at play and the role of agency in
bringing change to dominant logics.
The proposed study addresses these limitations by using a multi-level conceptual
framework to identify possible predictors to the adoption of new practices, and to
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interpret the findings. In particular, this study attempts to introduce the role of agency
into decision-making regarding the adoption of practices in substance abuse treatment, in
addition to exploring organizational characteristics and institutional demands. Further,
this study uses qualitative methods to enrich the knowledge of the various forces, such as
the role of agency and networks, contributing to or hindering the adoption of new
practices.
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Chapter 5
Research Design and Methods
Overview
This study proposes to explore the hypotheses presented in the previous chapter
using a mixed-methods approach. Qualitative interviews with managerial level staff at
substance abuse treatment centers in the greater Philadelphia area and New York City
were conducted. The interviews were semi-structured and explored perceptions of
treatment philosophy, the merging of substance abuse and mental health, managed care in
substance abuse treatment, services, funding, licensing and accreditation and personal
and professional networks. The content of these interviews was transcribed from audio
recordings and analyzed to reveal recurring themes and answer the research questions.
Secondary statistical analysis of a national data set of private substance abuse treatment
centers and their characteristics was then used to test the research hypotheses
quantitatively.

Qualitative analysis plan
In order to explore institutional forces and institutional logics, and the manner in
which they influence the provision of medication-assisted treatment, I conducted 30
semi-structured qualitative interviews with managers of substance use treatment facilities
operating in the greater Philadelphia area and in New York City. The first wave of
facilities was selected from a list of treatment facilities available at the Treatment
Research Institute (TRI) in Philadelphia, with which the investigators are affiliated. The
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TRI host the Delaware Valley (DV) node of NIDA’s Clinical Trials Network (CTN) and
therefore has contact with various treatment organizations in the area. Initial contact with
the mangers of these facilities was facilitated by the fact that many of them have worked
with TRI in the past. These facilities were in the Greater Philadelphia area. The second
wave was sampled through snowball sampling methods whereby managers in the first
wave referred me to other managers to the study or put me in touch with them, several of
these referrals were to facilities in New York City (a place frequented by the investigator
for another project).
Managers were contacted by phone and/or e-mail and the purpose of the study
and the reason for their selection was explained. A face-to-face interview was arranged if
they agreed to participate in the study (no one who was approached declined
participation). Interviews typically lasted about an hour. All interviews were taped and
transcribed. Interviews explored the types of services provided and the processes shaping
decisions to provide them and information about personnel, clientele, funding, treatment
philosophy, services and professional networks (see appendix 1).
Inclusion and exclusion criteria: Subjects had to be (1) one of the principal
decision-making managers of his or her substance abuse treatment facility, (2) able to
communicate in English, and (3) understand and sign the consent form.
Data collection and analysis: All interviews were transcribed by the author for
textual analysis. A grounded theory approach was utilized by the author to code the
interviews (Glaser & Strauss, 1967). Concepts that emerged from earlier data informed
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the coding of subsequent interviews. The first round of coding identified primary codes.
Subsequent rounds identified axial codes.
Concepts related to the content areas described in the literature review – coercive
and normative forces, competing identities, milieus and embedded agency were explored.
They were be used to further operationalize the quantitative variables described below
when appropriate, and to frame and enrich the discussion of the results.
Secondary analysis plan:
Sampling: The National Treatment Center Study (NTCS) is a family of projects
dating back to 1995, designed to document and track changes in the organization,
structure, staffing, and service delivery patterns of substance abuse treatment programs
throughout the U.S. For the proposed study, I used the NTCS, which is a nationally
representative survey of 405 private substance abuse treatment facilities, conducted
between 2002-2004 by a group of researchers at the Institute of Behavioral Research at
the University of Georgia. This is the fourth time this survey of privately funded centers
has been conducted (Roman & Johnson, 2004). This dataset is not available for public
use and was graciously made available to the researcher by the principal investigator, Dr.
Paul Roman, and his colleagues at the University of Georgia.
Centers were selected using a two-stage statistical sampling process to ensure
representation across geographic regions and inclusion of a wide range of treatment
facilities. First, all counties in the U.S. were assigned to one of 10 geographic strata of
equivalent size, based on population. Next, counties within strata were randomly
sampled. All privately funded treatment centers in those sampled counties were then
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enumerated using published directories, yellow pages listings, and survey sampling
databases. Centers were then sampled proportionately across strata. Over time, centers
that have closed or declined to participate have been replaced with other eligible private
centers from within the same geographic stratum, such that we maintain the geographic
representativeness of the sample and a target sample size of about 400 centers at each
wave of data collection (Roman & Johnson, 2004).
Eligibility criteria for centers: Eligible centers were those offering treatment for
alcohol and drug problems, at a level of care at least equivalent to structured outpatient
programming as defined by the American Society of Addiction Medicine’s Patient
Placement Criteria. Counselors in private practice, DUI / driver education programs,
halfway houses, and programs offering exclusively methadone maintenance services
were not eligible (a separate survey collected information about these programs).
Programs with methadone units were eligible if other (non-maintenance) addiction
treatment services meeting ASAM level of care criteria were available. Additionally,
because the research design focused on privately funded treatment services available to
the general public, treatment units based in correctional facilities and those operated by
the Veteran’s Administration were not eligible (Roman & Johnson, 2004).
Data collection procedures: Administrators and clinical directors of each
participating treatment center provided data in face-to-face interviews that were
conducted between 1995-1996. These interviews were repeated in 1997-1998, 20002001, and 2002-2004. This final wave of data will be utilized for this research, allowing
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for an exploration of early adoption of buprenorphine/naloxone (approved for use in
2002) compared to methadone, a medication that has been available for several decades.
Interviews focused on organizational structure, management practices, personnel
(number and type), case mix, and services offered. A particular focus was the centers’
adoption and use of various evidence-based treatment techniques, including
pharmacotherapies and psychosocial therapies for addiction treatment (Roman &
Johnson, 2004).
The NTCS is often used in studies examining the association between
organizational characteristics of substance abuse treatment programs and the adoption of
various practices and provision of services (e.g. Abraham, O’Brien, Bride & Roman,
2011; Abraham & Roman, 2010; Rothrauff, Abraham, Bride & Roman, 2011). Though it
is a large nationally representative sample, rich in its institutional variables, several
limitations with regard to this dataset can be anticipated:
First, the available data are cross-sectional and therefore any analysis cannot
include historical trends or changes.
Second, the available data include only private substance abuse treatment
facilities. Therefore, comparing privately funded facilities to publically funded ones is
not possible. In previous studies this has been a variable of interest (e.g. D’Aunno, 2006;
Friedmann, Durkin, Lemon, & D’Aunno, 2003; Knudsen et al., 2006). The NTCS
uniquely defines private centers as those receiving less than 50% of their annual
operating revenues from government grants or contracts, and collects data on the
proportion of funding from managed care sources. Therefore, we will use the proportion
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of managed care funding as a predictor variable. We will also explore themes related to
funding in our qualitative data.
Third, the survey did not include validated scales or other previously used
measurement for the concepts of interest. Of course, since I am conducting secondary
data analysis, it is important to note that the survey was not constructed with specific
goals of theory testing in mind, so not all measurements are theory driven.
Dealing with missing data: The NTCS is a very long survey conducted often over
several interviews. It is complex and overall requires several hours to complete. As such,
missing values occur in several of the variables of interest. Multiple Imputations (MI) for
handling missing values were performed. Imputation is the substitution of some value for
the missing values, allowing for complete-case analysis rather than list-wise deletion,
which can significantly reduce the sample size. Single imputation methods, such as
imputing with a single arithmetic mean value, are traditional methods for dealing with
missing values. However, multiple imputation is increasingly being used (Allison, 2002;
2010; Enders, 2010).
Multiple imputation is a 3-step process. First, multiple datasets are generated
according to a specified imputation model. In each generated dataset the missing values
are replaced with regression-estimated values. Second, data analysis, in which standard
analytical techniques are performed on each imputed (i.e., completed) dataset to obtain a
set of data estimates; the obtained estimates are adjusted for missing-data uncertainty
(variances). Finally, results are pooled from the completed-data analyses into one MI
dataset.
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Multiple imputation assumes that the data are at least missing-at-random. Another
assumption of MI is that variables in the model have a multivariate normal distribution.
However, the imputation method seems to work well even when this assumption is
clearly violated (Allison, 2010). Stata 11.0 was used for all MI and statistical analysis.
Allison (2010) recommends that the imputation model include all the variables
that are to be included in the regression models to be tested on the imputed dataset. Table
5.1 summarizes the variables included in the imputation model and details their percent
of missingness. Allison and (2010) and von-Hippel (2009) both recommend 'transform
then impute'. Therefore, continuous variables which did not meet the assumption of
normality were transformed before performing the multiple imputations, though
normality violations of variables may not pose a serious threat to the multiple imputation
parameter estimates (Enders, 2010).
Analysis: Means, standard deviations and frequencies were calculated for all
variables, and distributions were examined. In all analyses, the assumptions underlying
the application of all the statistical methods that are used (such as normality) were
examined, principally through the use of standardized residuals, influence diagnostics,
and graphical displays. Variables were transformed when appropriate. Logistic regression
models were used to examine the effects of the correlates described and in the hypotheses
above operationalized below on the dependent variables. In order to identify the most
parsimonious model, the significant correlates in each model were retained.
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Table 5.1
Summary of Variables Used in the Imputation Model and % of Missingness
(N=369)
Variable
% missingness
0
Currently treat with methadone
0
Currently treat with buprenorphine/naloxone
Currently provide MAT (methadone or
0
buprenorphine/naloxone)
0.3
State licensing
1.1
JCAHO accreditation
1.1
CARF accreditation
0
Parent organization medical facility (dummy variable)
1.4
Participation in research - ever
Use of ASAM to match client with appropriate level of
0.8
care
0.8
Use of ASI during intake
0.5
Active alumni program
Proportion of MC funding
20.9
Impact of managed care arrangements (mean of 17 items
13.3
on a scale of 0-5 each)
Orientation to medical/psychiatric model of addiction (0-5) 0.5
Proportion of clients with dual diagnosis
26.3
Proportion of clients who are relapsers
3.3
Proportion of clients with primary diagnosis of opiate
5.7
dependence or abuse
Proportion of counselors – MA level or higher
20.6
Proportion of counselors in recovery
19.2
Knowledge of CTN (0-5)
0.5
Alumni activity (mean of 6 items on a scale of 0-5 each)*
0.5
Manager tenure at organization (years)
2.7
Manager tenure in BH field
0.5
Age of organization
3.5
Facility size (# of admissions/FTE's)
10.6
12-step orientation (mean summary of yes responses to 4
0.3
questions)
Proportion of clients who are women
1.4
Proportion of women clients who are pregnant
2.7
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Variables and measures.
Dependent variables.
The unit of analysis in this study is substance abuse treatment centers. Using the
NTCS, provision of medication-assisted treatment is operationalized at the treatment
center level and is measured dichotomously – does the center provide methadone or
buprenorphine/naloxone (yes/no). Early adoption of medication-assisted treatment is also
measured dichotomously via the provision of buprenorphine/naloxone (yes/no), which
was approved for use in 2002. This wave of the NTCS was collected between 2002 and
2004, during the first couple of years from the introduction of buprenorphine/naloxone.
Independent variables.
The independent variables in this study are the various institutional forces and
logics operating in the organizational field of substance abuse treatment. I now turn to
operationalize each group of independent variables in accordance with the hypotheses
(see also figure 5.1).
Coercive Factors:
Data on JCAHO and CARF accreditation was collected (yes/no), and administers
were asked whether the center was licensed by the state (yes/no).
Type of parent organization - administrators were asked to report whether parent
organization was state/county, local, hospital, individual, corporation, religious,
university, private, board of directors or other type of organization. A dummy variable
was created for organizations whose parent facility was a hospital (yes/no).
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Proportion of managed care funding - proportion of managed care funding was
computed by dividing the amount of funding (in dollars) from managed care sources
(HMOs, PPOs, POSs) by the total revenue of the center (continuous measure).
Impact of managed care arrangements - Administrators were asked about the
impact of managed care on various organizational practices (each on a scale of 0-5).
Questions included to what extent does managed care: (1) recommend the content of the
treatment plan (2) change the content of the treatment plan recommended by your staff
(3) require that communication for authorization of further treatment be conducted with
the client's primary clinician (4) refuse authorization of further treatment even though
center staff recommends that treatment continue (5) require written communication by
members of your staff (6) require efficiency in your center's treatment protocols (7)
require members of your staff to coordinate care with health care or social service
providers on behalf of clients (8) require your staff to closely monitor client progress (9)
require verification of quality assurance procedures (10) require your staff to pay
attention to matching clients with appropriate level of care (11) require staff awareness of
effective treatment practices (12) require close monitoring of center's operating costs (13)
require close monitoring of patient charges (14) require negotiation for provision of
services (15) require negotiation for patient charges (16) require staff training and
development, and finally (17) to what extent has managed care led to the development of
new standard operating procedures in your center. A mean score ranging was calculated
to measure the level of managed care involvement.
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Normative Factors:
Attitudes towards medication-assisted were not measured in the NTCS, and will
be explored in depth using the qualitative interviews
The proportions of clients who are relapsers (have been in treatment for their drug
dependence two or more times), have a primary diagnosis of opiate addiction, and are
dually diagnosed were also assessed directly in the survey (continuous measure, assessed
by a direct question in the survey).
Competing identity logics:
Administrators were asked how many counselors employed at the center were in
recovery. Proportions of staff in recovery were calculated by dividing this number by the
total number of counselors at the center.
Administrators were asked how many counselors employed at the center held a
master’s degree or any higher degree. Proportions were calculated by dividing this
number by the total number of counselors at the center.
Centers’ emphasis on the 12-step approach is also operationalized at the treatment
center level. Directors were asked (1) whether their program is based on the 12-step
model, (2) whether attendance in 12-step meetings during treatment is mandatory, (3)
whether 12-step meeting were held at the center and (4) whether there is a direct effort to
link clients with 12-step programs at discharge. A composite score ranging from 0 yes
responses (low emphasis on 12-step approaches) to 4 yes responses (high emphasis on
12-step approaches) was compiled.
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Center’s emphasis on the medical model was assessed directly in the survey (on a
scale of 0-5).
Salience of milieus:
Connections to research – directors were asked if their center has ever participated
in research (yes/no), director knowledge of the Clinical Trial Network (on a scale of 0-5),
and use of standardized addiction measures to assess clients’ level of addiction (ASI and
ASAM).
Connections to alumni networks – directors were asked whether or not the agency
has an active alumni program. If the answer was yes, they were asked to what extent (on
a scale of 0-5) alumni were involved in 6 areas: (1) referring patients, (2) serving as 12step sponsors, (3) volunteering, (4) making charitable contributions, (5) serving on the
board, and (6) lobbying for funding. A mean score was calculated to measure the level of
activity.
Embedded Agency:
Clinical directors were asked to provide personal background. They were asked
about their tenure at the center and in the behavioral health field (in years).
Administrators were asked to report the age of their center. Size of center was
operationalized as the number of full time employees.
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Organizational Correlates of Medication-Assisted Treatment Provision
Institutional Forces
Coercive
State, JCAHO licensing, CARF
Parent organization - hospital
Proportion of managed care
funding, impact of managed care
arrangements
Normative
Managerial attitudes
Client profile (proportion of
relapsers, dually diagnosed,
opiate users)

Provision of medicationassisted treatment
Methadone or
buprenorphine/naloxone as a
treatment option

Institutional Logics

Early adoption
Buprenorphine/naloxone as a
treatment option

Competing identity logics
Proportion of staff in recovery
Proportion of degreed staff
12-step emphasis
medical emphasis
Salience of milieus
Research networks
Recovery networks
Embedded agency
Agency size
Agency age
Tenure of managers

Figure 5.1: Predictors of medication-assisted treatment and early adoption
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Chapter 6
Findings
Chapter Overview
This chapter presents findings of the study, both qualitative and quantitative. First, in the
qualitative section, I discuss the main themes that emerged from the interviews. The goal
of this section is to foster a nuanced discussion of factors that may be salient to
organizational service provision and adoption of practices in the field of substance abuse
treatment. In the quantitative section I first present descriptive statistics on the relevant
dependent and independent variables. I then present a series of logistic regression models
to examine the extent to which the identified organizational and institutional
characteristics (independent variables) affect the likelihood of providing medicationassisted treatment, being early adopters of medication-assisted treatment and providing
methadone (dependent variables).

Qualitative Findings
Thirty face-to-face interviews with managers and directors in substance abuse
treatment centers between were conducted May 2009 and June 2011. An analysis of the
content revealed that networks, individual agency and competing ideologies are
extremely salient factors in service provision and adoption of practices and that these
factors can either compliment or battle coercive and normative forces. Specifically, much
attention was paid by interviewees to the coercive and normative forces that play a
central role in organizational change, while simultaneously stressing the active role of
	
  

57	
  

	
  
individuals within the organization to promote or hinder change. For heuristic purposes,
the five central themes presented in the theoretical framework chapter, will be used to
frame the results. These themes were often complicated by personal attitudes and beliefs.

Coercive institutional forces
Coercive forces are associated with the control exerted by funding, licensing and
parental organizational sources. Almost all of the interviewees pointed to issues of
funding, licensing and accreditation as forces that hinder service provision. This was
particularly strong for managed care arrangements. One CEO of a large hospital-based
program said:
[The drug and alcohol field] has changed considerably. It has gotten much
more professionalized. Now it’s getting tighter and tighter with
regulations. [We] have to do a lot more for a lot less… [There are] HMO
changes and the behavioral health carve outs. All of that stuff has changed
how we do things … They [licensing and accreditation agencies] are all
over us. We answer to more people than you can think of. All of them
have different agendas … None of them line up, which is one of the
greatest difficulties. JACHO has their set of expectations and state have
their set of expectations and CBH which is the major HMO for Medicaid
recipients in Philadelphia have their expectations. It would be nice if the
three of them would talk occasionally and realize they are asking for the
same thing. But it doesn’t work that way. Each one of these individuals
who come with each given agency come with their own expectations and
their own biases as to what something should look like and how it should
be written in the treatment plan, how it should look like in the progress
notes. One person may think it’s completely satisfactory and another
person may look at it at from a different angle and say it’s completely
unsatisfactory. So we try to aim for the most stringent of the reviewers but
we still wind up missing the mark.
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The program director provided an example (similar examples were provided by several
other interviewees):
They [licensing and accreditation people] are stringent about a lot of
things. Especially how methadone is kept and stored. How it is spent.
They are specific about a lot of stuff. And it’s really difficult to get them
[to allow us] to modify [services] or get exceptions if they are seeking
methadone, that is, requesting opioid replacement therapy, then there are
very specific rules as to do who can get on the methadone program
regarding the rate of addiction etc. There are a whole bunch of rules. The
other services are not so stringent. Somebody can walk in off the street
and say that they are a cocaine addict, say ‘I want something to use’… In
all likelihood you can sit there and see what they need recipient and
probably can get them started [in treatment] and get the process moving.
This example also suggests that client characteristics (not being an opiate addict) may be
interacting with licensing (a coercive force) to influence certain types of services.
Managed care arrangements were discussed by many as hindering service
provision. One director, whose thoughts were echoed by several other interviews, said:
[Managed care] was a major problem when it first came in. Because they
don’t want to pay for anything... When they did decide to carve out
behavioral health - give it to CBH for Medicaid patients, it has worked
much more smoothly. A lot of bumps in the beginning, but worked
smoothly. They pay for designated services of substance but they do not
cover methadone treatment. They will not cover it at all. And that is,
unfortunately, an argument that we haven’t been able to win with them.
Another director of a public treatment center added:
I’ve seen that the people that they [managed care firms] are authorizing
are people who have had a shorter time of addiction. People who are
chronic substance abusers, they are not letting in treatment, and they are
the people who are more impaired and more in need.
The last quote, which also supports that client characteristics play a role in service
provision, was reflected in a number of other interviews. It is interesting to note that the
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director suggested that managed care arrangements prevent his organization from treating
clients with more serious issues.
A program director at a very large and established private organization described
how issues with managed care arrangements caused the organization to modify its entire
structure, also causing changes in the types of clients they treat:
When I first started here, we had county contracts. We did managed care.
At that point we were also were defining programs around that. We had a
short-term stabilization program, because that’s all managed care would
fund. At some point our leadership team decided that rather than designing
programs to meet other people’s needs, we were going to design
treatments to meet the patient’s needs. So then we designed programming.
It reminds me of the ‘Field of Dreams’ movie – if you build it, they will
come… So then we switched to a private pay facility. And so our patients
then choose to pay. And we can offer scholarship dollars in relation to that
… Our clientele currently are those who can afford it. Previously when we
had county contracts and things of that nature we were having patients of
the county that were sent here.
This director suggested that managed care arrangements prevented his organization
(formally a public one) from treating clients with more serious substance use problems.
While his organization was not willing to accept the situation and switched to private
pay, it seems that the new structure also prevents the organization from treating certain
types of clients – those who cannot afford their services. This supports the notion that
while managed care is crucial to making services affordable, it is also restrictive.
One director discussed issues of funding and managed care particularly in
reference to medication-assisted treatment. He suggested that different factors might be
influencing the provision buprenorphine/naloxone and methadone, a point made by many
other interviewees. Specifically, he suggested that managed care promotes the provision
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of methadone because it is a cheaper medication, while not giving clients an alternative
treatment options:
So, of course, now there is a big move to move to medicated assisted
treatment … the suboxone people and the methadone people. The
suboxone people are saying - and it does look to me like it’s a great drug that it is much better for opiate addicts because it’s the blocker … and it’s
not as addictive as the methadone. So I don’t know why people are
struggling with switching that off. Now suboxone is very expensive and I
don’t think Medicare pays for all of it. There must be some financial thing
to it. But methadone is pretty cheap. The idea of health choices, which is a
state initiative that PA has to follow, says that each client has the choice.
These clients clearly do not have a choice and how managed care is
getting away with it is they are saying ‘well, we are giving them a choice,
we are telling them you either go on methadone or you don’t go
anywhere’. Well, that’s not a choice. If the client says openly ‘I don’t want
methadone’ then they say ‘well, I’m sorry, that’s what we are giving you,
that’s your choice, we are giving you something’. So it is the genocide.
I’ve had a lot of parents call me, at least 10 in the last year, parents of
young heroin or benzodiazepine addicts, I’ve had 2 grandparents call me
… they went and bought suboxone of the street and detoxed their own
kids because they didn’t want to go back on methadone. So it is causing
another kind of unofficial system to go on.
Several interviewees discussed other ways in which managed care affects their
organization, as exemplified by the following quote. The director of a large methadone
program, discussing managed care oversight and education requirements, pertaining to
hiring decisions said:
[Managed care monitor us] in a couple of different ways. One, the most
obvious, they come in and say ‘you have service - show us the
documentation. And you better have the documentation available! ...
Another way they control level of care is through authorization of
services... So there is definitely oversight that way. Oversight and control
… it’s much more obvious with inpatient treatment, hospitalization,
residential. They are much more stringent than outpatient. Also, I have
seen that has probably resulted in elevation of the sort of minimum
education requirements. I can’t say that it has formalized anywhere. …We
used to be able to hire people with life experience. And they could be
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counselors with life experience and very little academic training at all… in
state recovery. Pennsylvania now has very stringent rules. The educational
requirements and experiential requirements to be called a counselor is a
minimum bachelor’s degree, preferably a master’s degree. So the folks
that we used to able bring on board, we can’t bring on board because of
the supervisory requirements that are imposed upon us. It’s just too
burdensome.
This last quote also hints at some of the complexities and interactions that might be
affecting service provision in the field. For example, while managed care might affect
service provision directly, it is also possible that it interacts with factors such as
counselor credentials, education and recovery status (competing identity logics) to impact
service provision indirectly.

Normative institutional forces
Normative forces in substance abuse treatment are characterized by managerial
attitudes that shape the norms associated with service provision, as well as client
characteristics that shape the standards of care associated with certain types of client
profiles. Managerial attitudes are the only force I was unable to explore in the
quantitative data set. Therefore, this section on normative institutional forces is
comprised of two parts: themes related to client characteristics are followed by a broad
discussion of managerial attitudes.

Client characteristics.
Interviewees often pointed to the unique or changing needs of their client
populations, and how these needs often determine the types of services offered and the
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level of care. They also pointed to changing needs of client population as a catalyst for
adopting new practices, particularly when those were in line with organizational
ideology. In addition to clients suffering from opiate abuse as well as clients with dualdiagnosis, many pointed to HIV status and demographic characteristics of the clients,
such as age, race, religion and gender as influencing service provision. One director
discussed his program’s opiate addicted clients:
We have patients on methadone for a long time who are very low dose and
they just do not want to detox. Nobody says that they have to go. We have
to accept people with such high dose that they are a danger to themselves
and everybody else. We use to have a cap of 80mg of methadone. In
Philadelphia it’s just not sufficient. So they have done away with caps. A
lot has changed because everyone was requesting exceptions.
While this quote exemplifies how client needs and desires were instrumental in
modifying an organizational practice, this next quote, by a director of a women’s
program, suggests that normative forces have an effect but that they take a back seat to
organizational ideology. It also suggests that client characteristics might be interacting
with each other to influence service provision (in this case opiate addiction and gender):
That program also is a fairly traditional 12-step program. The women's
treatment plans are all about what steps are you on. We do use methadone
for maintenance for women who are in pregnancy, but then detox them
after.
This was not the case in another 12-step oriented program that encounters pregnant
women who were opiate abusers. Rather than provide a service that is at odds with the
organizational ideologies, this organization does not accept pregnant women into
treatment. The program stated: “We don’t accept pregnant women who are on opiates,
mainly because we don’t do maintenance, and that’s what they need.”
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Many other interviewees discussed methadone in the treatment of opiate addicted
women in general, and pregnant women in particular. Methadone, though often viewed as
replacing one addictive substance with another, was generally more acceptable for this
population, even if not adopted in a particular organization.
This next quote by another director of a women’s’ program discussed how her
personal views towards methadone for pregnant women over the years have shaped
services provision, suggesting that her long term embeddedness in the field might be
interacting with normative forces to influence service provision.
We’ve seen a tremendous increase in the number of clients that they are
forcing on to methadone. But everybody knows that I caused a big hoopla
in the city when I was working for a women and children’s program - used
to be straight D&A. It is now a methadone program. Before it turned into a
total methadone program I was responsible for evaluating face-to-face
interviews with all the women who were going over there who were on
methadone. Well, I had a real problem with all this, because most of the
women who were coming to see me were pregnant, and they were really
dosed up. So dosed that they could not really participate in the interview,
nodding out, really out of it on very high doses of methadone - which I
kept denying them. I said ‘something is wrong here’, I made a big stink
about it and the medical director over there called me because I said
‘aren’t they like breaking the law? I don’t think you are allowed to have a
certain amount of dose.’. Well, I learned a lesson then, too. Because when
you are pregnant you can be on a very high dose of methadone because
your fetus takes more of the methadone. I said ‘well, ok, but I think they
on too high of a dose’. They couldn’t even sit, they were really literally
nodding out. But we admitted them and what happened was I was trying to
stop, I was resistant to the organization turning into a methadone and
children’s program, but I lost that fight because I was the only one.
Nobody else cared. So here they are now - a methadone women and
children’s program. But I hired some of the people who worked there, too
and they said what happens to those babies afterwards, it’s inhumane.
This director, who was unable to change her former organization’s practices based on her
experience and beliefs, mentioned it was the main reason she left that organization. She
64	
  
	
  

	
  
chose to work for an organization that does not treat pregnant opiate addicts with
methadone.
Another director of a therapeutic community pointed to the complex relationship
between client characteristics, funding and organizational philosophy:
Our philosophy is abstinence. We only have one program that is a women
and children program that takes chronically mentally ill women and their
children. The only way we were able to get this grant is that we had to sort
of get in bed with them and say – ok, if you have a methadone woman, we
agree that we will take one or two of them. But other than that we don’t
have maintenance, nothing like that because the concepts and just the
values of the therapeutic community are abstinence, drug-free.
Another director of a program for adolescents explained how working with adolescents
has led to treatment practices that are not necessarily in line with the organizational
ideology, at least initially:
Our company is an abstinence-based program. ... That being said, you deal
with adolescents, you have no option but harm reduction at times … When
you are moving somebody through the stages of change, and then they
come in not ready for abstinence and you have to then prepare them for an
IOP and meet with them individually. So you are trying to reduce their
risk while moving them along.
Therefore, while encountering and treating pregnant women might facilitate the adoption
of methadone by some programs, long-term methadone maintenance for women who are
not pregnant remains an unacceptable treatment option for this organization because the
practice is seen to be at odds with their 12-step ideology. Similarly, encountering and
treating adolescents might facilitate harm reduction practices in an abstinence-based
program.
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Race and religion were also described by several interviewees to affect service
provision. One director pointed to disparities in service provision for Latino clients:
We’re smack in the Latino community here … a mono-lingual person,
their choices are way limited to where I can send them, as oppose to
somebody who can get by speaking English. And [even when they get
treatment] the services then differ in terms of the quality. Shouldn’t be that
way, but it’s the way it is. Now we are starting to look at that whole
disparity issue, which affects our approach to public health…. So there is a
whole disparity going around in terms of the amount of services that we
provide.
Another director at a large private organization pointed to clients’ religious and cultural
needs as promoting service provision, while giving the example of orthodox Jews:
I think one of the things that absolutely sets [my organization] apart…is
our pastoral care – the spiritual side of things is gigantic. It’s a gigantic
gap in most using drug addicts’ life, and alcoholics’ life. And it’s
something that needs to be addressed in treatment and in recovery. And
our pastoral services ability to meet [our clients] in a meaningful spiritual
way, that age group, very difficult to do – they do it beautifully. It’s a huge
part of what we do. In fact, one thing we do as well as any treatment
center that’s not affiliated with a specific religion. For instance, orthodox
Jews choose this organization … for a number of reasons. We understand
Judaism and what it means to be a recovering Jew. We have a Rabbi on
staff ... we have any number of minority kids, and especially minority
religion, Jewish being the most well represented. So I think it’s not
atypical to have 10-15% Jewish clients, and a decent percentage of them
even orthodox. Kosher kitchen, understanding of the orthodox tradition,
needing to sleep parents close to campus or even on campus during family
weekend so that they can observe the Sabbath. I think you are going to
find that [here], always a willingness to have that level of customer
service. If you ask we are going to try and get it don’t. We know our
limit’s, but if we can we are going to get it done. So a kid coming in, a
Jewish kid who is not Kosher and not orthodox, a lot easier perhaps.
We’re still going to offer Temple, still going to offer Rabbi services, but
they might not be as invested. But a true orthodox, who needs all the other
stuff that we have, we are going to get their needs met, too.
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Many of the directors discussed clients with dual-diagnosis, and how the field in general
has evolved to accommodate them, via the recent merging of substance abuse and mental
health. One director described how changing practices in his organization following the
merging are also impacted by demands from funders:
… You can’t really separate them (SA and MH) completely because all of
our clients have some kind of MH issues, even if it's just depression. ...
However, the other thing that sometimes people don’t realize is that there
is a huge variety in dual-diagnosis clients, so you have dual diagnosis that
are primarily MH and their D&A is secondary, you have clients that are
the opposite – the D&A is primary and the MH is secondary, and then you
have the in-between. So sometimes program funders want us to be able to
treat everybody and say ‘well, you are dual diagnosis, you should be able
to handle somebody with MH’, and that is just unrealistic because certain
types of disorders have to be treated in a different way. It’s like mixing
apples and oranges. These are the issues for this population, even though
they have a common thread - they have dual diagnosis and they have more
than one issue – it doesn’t mean that they are all in the same boat and they
require very specialized treatment. But I think that it’s kind of unrealistic
to expect that you can deal with one and not the other or deal with them
completely separately.
She was not the only one who described some of the issues arising from providing
integrated services. Another director states:
Our day IOP is always a dual diagnosis because if they [clients] are not
working, it’s usually is a symptom [that they have] mental health issues. If
someone is coming in with bipolar, major depression, generalized anxiety
disorder – they will have a life counseling clinician while they are in IOP,
and their psychiatrist. So we use all these to become more integrated
although we don’t have a really sophisticated model. We are working on
that. We are trying to figure a way that we can work with more integrated
clients. And we are published as a dual diagnosis agency. And we’re not.
The last two quotes, by directors discussing the merging of substance abuse and mental
health, can also exemplify competing identities in the field, suggesting again that multiple
factors interact to influence the types of services offered.
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Managerial attitudes.
As mentioned above, managerial attitudes towards medication-assisted treatment
were not assessed in the quantitative dataset, in which the unit of analysis is the
organization. However, this theme was explored in the interviews. Attitudes of
interviewees were more often than not in line with the organizational philosophy of their
organization. Methadone was viewed by many of the interviewees as part of the harm
reduction movement, and entirely contradictory to 12-step, abstinence-based approaches.
Several described it as replacing 'one addiction with another'. Attitudes towards
buprenorphine/naloxone, on the other hand, were more favorable and, when discussed, it
was mostly viewed as a medication for the treatment of addiction.
One director in a 12-step based program (who used the terms methadone and
harm reduction interchangeably throughout the interview) said:
I’ve never heard it to work, for me I just can’t imagine that it would work.
I just think it’s a rationalization for people to continue their use. To tell
you the truth, I think that some people who promote harm reduction in
those cases, probably they are heavy drinkers. That’s my theory about it
and saying they don’t want to tell somebody else ‘give it up completely’
because they don’t want to give it up completely because they can’t
imagine doing it themselves. And I’m not saying that in other fields its
bad, like HIV does a lot of HR and that’s a whole different story, but when
you are dealing with addiction I just don’t think it makes any sense.
Another director who also used the terms interchangeably expressed a similar view:
Personally I don’t subscribe to that. I don’t believe in the harm reduction,
mainly because I think to some degree it negates the disease concept, and I
believe in the disease concept and the medical aspect of it. And so I
believe you can put the symptoms in remission. My own take. At the same
time, I know it exists. I respect people who do that, and I do believe there
are some patients that just like methadone, although I personally would
not work in a methadone clinic.
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A third director said:
I believe personally that [harm reduction] is a dangerous philosophy and I
also believe that that kind of stuff – harm reduction or moderation
management or any number of those things – they are beautiful marketing
tools for the addicted brain, which is always looking for an easier out.
When you are a drug addict, when you are an alcoholic, that’s a great
marketing tool. If I’m a person considering treatment or if I’m getting
pressed into treatment, harm reduction – that’s beautiful. That’s where I
want to go to rehab. Because that model falls right into line with my
addictive thinking pattern. So I espouse … a 12-step philosophy and an
abstinence-based model that I am completely comfortable with, and
frankly if an employee comes here, and is not comfortable with that, or if
they come to interview, it’s not going to work for them here.
These three quotes, reflected ideas brought up in several other interviews, equate
methadone provision with harm reduction, which was not viewed favorable by many
interviewees. Another director, whose organization has adopted buprenorphine/naloxone
for detoxification went further to criticize the manner in which organizations provide
methadone to their clients, especially their younger clients:
I think Suboxone is probably better [than methadone]. I have, in all my
years of working with addicts, have never found anybody to do well on
methadone, because the methadone clinics in themselves, just the
environment and the atmosphere has so many addicted things going on –
people are dealing drugs, people are using – there really isn’t any clinical
treatment going on in the methadone programs and people just go in to get
their juice and leave so it perpetuates the dependency and real unhealthy
behavior. And they put people on such a dose, they start them and they go
up such a high dose that people can’t just stop going, they have to keep
going. And they bring them down very, very slowly – they pump them up
really quickly and bring them down slowly. But there is nobody who is
really challenging them, nobody who is really evaluating them, no one
really doing that because it’s a big money maker and they are very well
protected by the city. So nobody has really exposed really what’s going
on. We’ve had a lot of staff that has come here, who works for us now,
who worked in methadone programs and they tell you stories that are like
horror stories of young kids. [I was told] that in this one methadone
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program … they are seeing younger and younger and younger kids – 18,
19 year old kids are on high dosages of methadone. And when they are
done [with treatment], and they keep getting the methadone, they are
getting high and they are young, they are not even heroin addicts, they are
benzodiazepine addicts, so any opiate, benzodiazepine, Percocet, anything
like that, they are throwing everybody on methadone. So I’m not a promethadone person, even though I have a friend, who has been a
methadone doctor forever, and she’s a good friend of mine. We’ve had
some heavy conversations about it. But in the purest sense if you talk to
people, in the purest sense of what they think should happen, if it really
did happen that way – then, ok, it would be great, but it doesn’t. In reality,
it doesn’t happen that way. There is a lot of riffraff.
This suggests that views towards buprenorphine/naloxone and methadone, though both
medication-assisted treatment might be quite different and that it is possible that different
factors influence the adoption of each. This statement also lends support to the hypothesis
that certain characteristics of clients served by the organization might be influencing the
types of services provided, in this case age. The same director provided an example of
how his views towards methadone for younger clients played out to determine a course of
treatment:
There is one psychiatrist … who I’ve worked with for many, many years...
We just had a 20-year old kid, she just turned 20. He said ‘look, … she
can only go to methadone’. She’s been using heroin for 5 years, been in
and out. Well, I said to him ‘she was an adolescent when she started
using’. We have to keep everything in perspective. It’s not like an adult
who’s a chronic user, this is a kid who was in high school. And I said to
him ‘give us a chance we will put her on suboxone here, let’s see how that
works’. He said ‘ok, I’ll do it’. So we had her here, she stayed on
suboxone, she completed treatment, he was quite surprised because she
runs every time, but people who are on methadone there is nothing else
happening, I mean, that’s all they are doing is getting dosed every day.
There is nothing else, nobody is dealing with any of their other issues and
addiction is a symptom. If you don’t deal with everything else, people are
going to keep using. If it was that easy that we would just give everyone a
dose that the substance abuse field would be done. We wouldn’t be as big
as we are.
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A director of a 12-step based women’s program shared that her attitude is to ‘be open to
what works’ and that she often questions her organizations’ practices. She said:
Sometimes I will question [why we don’t have a longer detox]. … And
then whenever I see any kind of article that looks at longer detoxing I send
it over to the medical director ... We have family education and patient
family members have to go through the family education day before they
can come visit their family members. And so there is a rule that if the
person … looks like they are high or actively, or if the patient tells us that
they are actively using then they are not allowed to come in for the family
education. I can see how that somewhat makes sense …Their more likely
than someone else to you know try to sneak drugs and stuff. But one of the
counselors said that so and so boyfriend shouldn’t come in because he's on
methadone. And I hit the roof! He’s taking a legal medication. He’s taking
it as directed! Is there any evidence that he’s abusing it?! [I told them]
Lets just pretend its insulin and that's how I [got him in] … My feeling is
that you can find a way to manage without medication is better than with
medication because medication is always going to give you side effects.
… but not everybody can do that. Some people need insulin, their diabetes
is just so whacky that they can’t control it with diet and exercise, and
that’s how I explain it to the staff. And it’s wrong to penalize and to
stigmatize those people.
Her explanation, which was also given by several other interviewees, introduces the
diffusion of the medical model into the field. While some of the interviewees stressed
their support of this model, others were open to it, yet preferred to leave decision-making
to medical professionals. For instance, one director, who has recently entered the
treatment field, admitted her lack of knowledge:
He had the modality that it’s just safer to be on it forever. So I would give
him clients, and he’d have no reason to taper them, to take them off. I
don’t really know what to do with suboxone clients, if it’s safe to keep
them on. Parents ask me ‘what do you think? How long should they be on
it?’ and I say ‘it’s up to your doctor’. I’m going to stay out of that one. I
don’t know.
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Another director shared his attitudes towards methadone and buprenorphine/naloxone,
suggesting that attitudes might be influenced by knowledge of research in the field:
I have thought that it is safer to stay on [suboxone]. If it’s going to keep
you away from smoking or blowing or using oxi, than stay on it.
Especially, I have a client that’s in his 60’s. Tapering him off suboxone
right now, he’s only on like a tab and a half a day, if it’s going to keep him
away from Heroin then I’m comfortable with it. But we also have clients
that do the dance. You know, who are getting high, using the suboxone for
the buprenorphine/naloxone effect and then those who are crushing and
injecting it or selling it because the street market value is so high. … I also
think there are some side effects to any drug. There’s urinary retention,
problems with constipation, definitely sexual side effects with suboxone,
like any other anti-depressant. I’m mixed about it. With methadone, my
only fear with that is people, places and things. It’s so much easier to
abuse. For every motivated client there are 10 who aren’t, but I don’t have
a whole lot of experience with methadone. But I just know that would be a
fear of mine. You know, what kind of care you get. So I’m as much for it
as I am against it, I guess. I’m not really against it, I need it.
A CEO of an organization who has provided methadone maintenance for years expressed
very favorable attitudes towards medication-assisted treatment and talked about how
years ago he was able to get his clients treatment in another organization that was initially
unwilling to accept them:
The guy who is the head of [another organization]… We used to have
these knockdowns, when we got to meetings we get into these huge fights
about methadone vs. drug free [treatment]. Now they take patients with
methadone, they are a little more open to it, but still, these communities
really do not like methadone clinics.
Another director, who has been in the field for many years, discussed how his views have
changed based on a newfound understanding of the disease model. He went on to
criticize drug-free settings that are not open to incorporating medications of any kind in
treatment:
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I didn’t really truly accept the disease concept until like 1995. That was
my own personal issue – there IS brain chemistry here involved, and that’s
why this person isn’t getting this. It was never a moralistic issue with me, I
can say that, I wasn’t on that side of the fence. But I was ‘this person isn’t
doing anything to help themselves’ and I think that’s part of the disease
itself. So (in 1995) I really got an open mind and started looking at why
medication is important and why therapy is important. I don’t think you
can be effective if you do one OR the other. There are some programs, I
won’t name them, but there are programs around that believe in the [drugfree) therapeutic community and they beat stuff into kids… It’s funny
because there’s still a perception in our communities regarding
medication, and that if you take medication you are bad or you’re weak.
We’ve been trying to squash that stereotype by working with our families
and getting them to say ‘just like a diabetic’. A diabetic has to take insulin.
You don’t call them weak or bad. So we really work with the disease
model to get them to understand that there is brain chemistry involved
here and that’s the way it is.
In sum, it seems managerial attitudes towards medication-assisted treatment are tied to
controversy in the larger institutional field between the 12-step abstinence-based
orientation and the medical orientation. Also, while many interviewees equated
methadone maintenance with harm reduction (not viewed favorably by many regardless
of their personal definition of the term), this was less often the case when discussing
buprenorphine/naloxone.

Competing identity logics
Often different sets of organizational actors adhere to different identities and the
ideologies associated with them. As motioned above, a prevalent theme that was brought
up and explored in depth was ideological clashes within the field of substance abuse
treatment. In particular, interviewees discussed conflicts based on the merging of the
more traditional abstinence/ 12-step /AA model service providers with a drug and alcohol
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background (often in recovery) with the medical orientation of the people coming into
substance abuse from the mental health field (often with a higher education).
A clinical director of a program at a large organization discussed recovery status
and education among clinicians and counselors. He disclosed that he was both in
recovery and had a master’s degree, which was not common in his organization. He
suggested that while many counselors in recovery also have degrees (mostly bachelors),
there are philosophical differences between those who are in recovery and those who are
not, that might be influencing the services they provide:
There are a lot of people that are in recovery. Depending on what position,
you could have as many as 50% in recovery … there are some recovering
folks certainly with bachelor’s degrees, and even a few more with masters.
I think if you come to work here, strictly without “formal education” but
through 12-step and recovery, you’re going to have your own set of ideals
that are going to have to intertwine clinically with some of the ideals that
perhaps psychology, MSW might bring, that are non-recovering people
with those degrees. So, I think there are some differences in expectation,
and some philosophical differences in how you might address a certain
behavioral symptom, and how you might intervene on said behavioral
symptom. There might be some differences between how a recovering
person would do that without an education, a psychology or social work or
counseling degree, and how someone with a degree and no recovery might
interact.
Another director gave an example of how people who have been through 12-step
programs and are in recovery have a different focus in treatment that people with
professional backgrounds:
Mainly, 12-step is a lot more didactic. And typically someone who comes
from a more clinical psycho-social work background they may
incorporate, try and create more of a group therapy setting, where they are
using psychodrama, empty chairs techniques, different group activities,
having a big array of strategies. ... So I kind of see a lot more process
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focused, sometimes with the traditional clinical background, whereas
without it it’s a lot more client talking to clinician.
One director of a program for youth explained that it 'used to be us (i.e. substance abuse
treatment) and them (mental health treatment)'. He went on to elaborate:
To me substance abuse is a brain issue. Mental health –also a brain issue.
You can’t have it both ways. You can’t say I’m an addict or an alcoholic
and I don’t have mental health problems. We find out when we really sit
down and look, most of the people that we deal with begin to use drugs or
alcohol for emotional reasons. It is a crutch, it either calms or develops a
part of them that they need for stability. … The part that I don’t get. Well I
do get it, because all the funding happens and that’s why people want
substance abuse and mental health to stay separate. The D&A folks say ‘if
we merge the mental health folks will take all our dollars’ the mental
health people say ‘well, those D&A people are too concrete’. But the one
thing, and I came from the substance abuse side, that the mental health
people have over the substance abuse people: substance abuse people
expect you to go to treatment and get better immediately. Mental health
people have it in their minds that you are a client for life. And that’s what
we, the D&a side need to move to … it really is archaic, because the fact
of the matter is it’s chicken and the egg – what came first? The mental
health and then the substance abuse? It doesn’t matter, you treat them
simultaneously!
A director of a methadone program discussed some of the challenges to the blending
together of traditional substance abuse and mental health, and how it can affect many
aspects of the organizational structure. He also pointed to a possible solution, via hiring
of new personnel that are ‘dually-oriented’:
It’s been very, very hard. And so there have been a lot of failures on trying
integrate them. … We can force people to work together, but then they
come up with ways ‘we are going to separate the waiting room ... all the
drug and alcohol people will be in this wing and we’ll be in the other
wing. And that just naturally happens. They naturally kept away from each
other, they naturally had separate staff meetings. We would try to combine
the beds and they would still sit apart from one another and there was a lot
of gap(?) even at Christmas parties, holiday parties, they would not
mingle. … So we hire new people and we bring in people who do both.
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We hire them immediately to take on both. It’s kind of hard to take the old
school drug and alcohol person and their biases and it’s usually around the
AA model, abstinence only. There is nothing else and they can be working
with a bipolar and never refer to a doctor because you don’t take drugs.
You just don’t take drugs. We want to get passed that but it’s hard. … I
am not going to change them. But we’ve been very successful in bringing
in and hiring new people. We ask ‘what's your experience with mental
health, what's your experience with drug and alcohol?’ … They are less
prevalent to be in recovery themselves... they get both (the substance
abuse and the mental health) and they want to work for both. So they’ll
see individuals for mental health and they will also be able to run a drug
and alcohol group. That’s been successful. I mean we don’t know what
percentage… Probably a third of our organization consists of those people.
I can see that over the years it’s went up from zero up to a third and as we
hire, and the old people retires or those who are part time, we are only
bringing in people who will integrate stuff.
Another director added, who disclosed his recovery status and described himself as
adhering to the ‘old school 12-step model’ said:
Personally I struggle sometimes. It’s different work, it’s a different way of
looking at things. The downside to this whole co-occurring movement is
it’s great to diagnose that someone has depression, but people are still
foggy. If they don’t stop drinking, an you’re just going to take and
approach to treat the depression, you’re not going to have good outcomes
… So it’s an interesting phenomenon that’s happening. What I’ve always
worried about from a D&A standpoint is in behavioral health D&A has
systemically always been slow. If you look at [the director of one of our
other branches], he has a mental health background. … A lot of times has
a blind side to some of the addictions stuff and he admits it openly. He’ll
talk with me or [our CEO] about it and say ‘well, what do you think about
this?’ ‘I have some real concerns here philosophically about how that
might affect the way that we do things.’ … I kind of look at my role as
protecting some of the old school stuff, but being open to the new ideas,
and how do you make that merge. ... So what I want to make sure the
D&A component doesn’t get lost is if somebody is doing a co-occurring
group where mental health is more the focus. … And I think some people
are purely mental health and they miss the D&A piece or they don’t want
to go there all together, or they have some outer counter-transference
going on.
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Several directors pointed to academic training as lagging behind changes in the field, as
exemplified by this next quote:
I think the combination of the two - that merging - has been beneficial.
Frankly, I am not sure though that the educational arena has caught up to
that. And what I mean by that is - I am responsible for a lot of hiring of
staff. And I find that people depending on what school they have gone to
have a different turbulence. They either still looking at a patient through a
MH lens because that how they have been trained or they are looking at
them through an addiction lens because that is how they have been trained.
I find it rare that someone just coming out of school and kind of have that
full broad picture.
In sum, while most directors acknowledged that being in recovery and belonging to the
‘old-school traditional AA model’ and coming from a mental health background are not
mutually exclusive (or exhaustive of people’s orientations in the field), it seems views
differed on which background had more influence on service provision. This was
particularly ambiguous since it was noted that many people who are in recovery went
back to school to get their credentials and/or degrees (often because of demands by
licensing and accreditation agencies as well as managed care firms).

Salience of milieus
Organizational actors belong to networks and milieus that are marked by
particular cultural practices and beliefs. Knowledge of current research and evidencebased practices was often mentioned as a factor that affects service provision in general
and adoption of new practices in particular. This was particularly true for organizations
whose directors were affiliated with TRI, who helped facilitate the interviews. One
director of a methadone maintenance program simply stated ‘the research has been very
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clear that to artificially impose a low dose [of methadone] just doesn’t work. So now it’s
different.’
Another director discussed large-scale changes both in the field and for his
organization that he believes can be largely attributed to what research milieus share with
organizations:
… ‘meeting the client we’re he’s at’, is the biggest change I’ve seen from
when I’ve started in the field 25 years ago. I think we made a lot of
mistakes early on in D&A. It was very confronted, and more about tearing
down the ego. …I don’t think back in those days we took into account that
people are individuals, there personalities are individual, and so is what
works. You can’t always go cookie cutter. That might be better for the
organization than it was for the client. TRI has been responsible, I keep up
on their research and stuff. Trying to talk people into more a disease
recovery model, if you relapsed 25 years ago it was like you discharged
the client. … This is something that I found fascinating – we changed our
model because of it: when we first started out, [our program was] 5 nights
a week, 4 hours a night. And then one of the first rounds of TRI research
they found that it’s more important to have contact with the center, but it
doesn’t have to be 5 times a week. After that first month, it could be twice
a week, or once a week, or at the 12-18 months it could be once a month –
people checking in – and outcomes don’t change that much. I found that
fascinating and have taken that whole mentality. When people come in
now, it’s not like they are here for mental illness anymore, they look at it
like ‘you can do a course of treatment, but keep in touch and stop in, and
call us before you relapse.’ And you can do that, and I think it really
makes a difference.
One director discussed how methadone has been shown to be effective in numerous
studies, yet is not widely adopted. His point also lends support to the suggestions in
previous sections that ideological conflicts may hinder the adoption of practices and that
methadone is not compatible with abstinence-based approaches to treatment:
I think the current administration of the behavioral health is really trying
to bring methadone in as part of just another vein of treatment. I think
there is much more acceptance. But you have to realize in this field many
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of the basics were established early by the national council on alcohol.
The 12 step and only AA, abstinence all the way. And methadone is
perceived as just another drug that they are abusing. So even narcotic
addicts who go to narcotics anonymous don’t necessarily accept
methadone.
A director of an organization that offers a needle exchange program discussed how his
organization tries to use research to lift the ban on needle exchange, unsuccessfully.
We’re fighting, trying to get the federal ban lifted from funding syringe
exchange. Because there is a federal ban that doesn’t let us use federal
fund to actually fund a syringe exchange. We can fund ancillary services
to it, but not the actual exchange. We can’t buy syringes with federal
money. We think we are close to getting the language lifted. That’s all
about the science at this particular point. And in Philadelphia it makes a
lot of sense, because, you’re spending 7 cents a syringe. It’s $200,000 to
treat 1 person with HIV a year. It’s just common sense. It makes a huge
amount of good sense, even from a financial perspective, which is an
argument that we get to make. Never mind the health stuff. People in
government are interested – spend a dime rather than the $200,000 you are
going to spend. That’s what it’s come down to, so I do think we’re at a
point where thanks to research we can make these kinds of valid
arguments… You know, they are supportive of us for the most part, they
hear it, but it’s politics. And that’s the thing that floored me. For the most
part, people want to do the right thing. In our political system, our
politicians want to do the right thing, but they also want to stay in office.
And so we have to figure out ways to help them do that so that they
support us.
Several others also argued that research findings could be a catalyst for organizational
change, as long as they do not clash with prevalent ideologies in the field or societal
values. One director described the process his organization goes through before
disseminating a new practice. He clearly stated that a new practice would not be adopted
if it is perceived to be at odds with the organizations treatment philosophy, even if there
was ample research to support it, giving the example of harm reduction:
Typically our process here when we get new information we disseminate
it to our clinical oversight team, and it gets discussed and debated and that
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sort of thing. To determine first and foremost if it fit’s into our philosophy
of treatment, and then if is there a lot of research that backs this up vs. a
on- time thing. And so once it goes to clinical oversight, it’s debated and
then decided whether or not we are going to use it or not use it, and then it
gets disseminated to all staff… I know harm reduction exists ... There may
be all this research with harm reduction, [but] it doesn’t fit into our
philosophy of treatment, and therefore it would not be disseminated.
Several of the organizations whose directors were interviewed mentioned they employ
alumni (from their own program) and that many alumni serve on their boards. A couple
of the directors pointed to alumni as being instrumental to organizational practices. In one
organization, a director stated:
If it’s an organizational decision, many times involved is our leadership
team, with input from board members, our board of directors. Our
strategic planning process also involves some of our referrals, some of our
employees and some of our former patients. Our main referral source is
our alumni…. When individuals leave [treatment], they have to have a
continuing care plan. So that could be us referring to an outpatient
therapist, a marriage and family therapist, a halfway house, whatever they
need following their stay here.
She later attributed this continuing care plan to lessons learned from former patients.
Another director, while discussing where he gets his information, mentioned that research
is important but that the most significant knowledge about that field and what works
comes from their alumni:
I get it [my information] from people that know the field. Colleagues,
people I meet at a conference for instance. Families ask for it. It’s not
atypical for a family to say ‘hey, this kid can’t come home, we can’t do it,
the kid can’t do it, what’s out there?’ And we have people that research,
we have people that travel to different places and look around, ask the
right questions. We have people who come here and tell us about their
stuff, their place. But the biggest single person that speaks to us, or back to
us is our alumni – ‘here’s what we did after [we left treatment here],
here’s what works for us, here’s what was lacking’. Our alumni tell us,
and keep us in the know.
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Embedded agency
Institutional logics scholars contend that organizational actors and organizations,
embedded in organizations and institutional fields, have the ability to shape these
processes themselves. Accordingly, in this study, almost all of the interviewees discussed
how they found themselves in substance abuse treatment. Half of them disclosed that they
were in recovery themselves and many of them have been in the field for at least 20
years. A central theme that emerged was how their personal experience and long tenure
(which is often accompanied by many personal and professional connections) shape their
attitudes on one hand, and provide them with opportunities and leverage to affect
treatment and service provision on the other hand. One director said:
When you’re in D&A it’s kind of a knit community, so when you open up
a new center I just kind of use my name, go in there, make connections…
I’ve been in personal recovery 27 years so a lot of people know me from
NA, AA. … I have families, they call, I treated their son or daughter years
ago [another organization]. I’ll get back to them and say I don’t work there
anymore clinically, but I can put you in touch with the manager down
there. Or if they tell me a situation, I’ll say X might work better with your
son because what his personality and specialty is. So that’s what they do.
And I think it’s from being an old head, from being around so long.
One director discussed how his organization’s medical director stood between him and
getting a new drug approved for use at his organization.
So our medical director is really not impressed with [a new drug for
alcohol addiction]… [He says to me] 'I read the report …, it just reduces
alcohol usage, it doesn't stop it'. … It's not supposed to stop it! It's
supposed to help the patient think before taking another drink. It's
supposed to be used as an aid, but he talked to [our CEO] about it and
[told him] he's not impressed. So no new medication here.
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Another director discussed how she established a program for women. Following her
own recovery and years of professional experience, she realized that many women had
unmet needs:
So about 15 years ago, I realized that there was a need for co-occurring
treatment for women because back then D&A and mental health were
separated and there were 2 pots of money. I really wanted to create a
program … were I used to work, that would serve women who had cooccurring disorders, because it was a big treatment gap back then. …
When I first came to [this organization], it wasn’t the program it is now.
It’s been 15 years, but I’ve been able to create into something that I felt
that women need.
These quotes, which also touch upon the merging of substance abuse and mental health,
the influence of research in the field and the coercive nature of various funding streams
exemplify how embeddedness of individuals in organizations and institutional fields
interacts with other forces that are at play to influence service provision and adoption of
innovation.
Similarly, directors of older and larger organizations talked about how their
organizations were able to resist certain changes in the field while promoting others. One
director of an old and established private treatment center talked about how his
organization was one of the pioneers in bringing in mental health aspects into treatment
with adolescents, which caused many employees who had a traditional substance abuse
background to quit:
So at [this organization] we decided we were going to be at the forefront
of offering a new kind of rehab services, a transition, so that we’re not
calling it D&A rehab. That we really were providing some real therapy to
kids, figuring out what was going on, that drug use is one of the things
that’s going on, but it’s not everything that’s going on, and then really
combining that, moving that on… So we brought it mental health. It was
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difficult because it was a really AA/NA model, they were saying to kids
‘you can’t follow this rule, you’re out’. And I never understood that in
treatment anyway, part of treatment is picking up again. That’s just part of
it. So to kick somebody out for using, doesn’t make sense to me, because
that’s why they are in the program in the first place. So we had to begin to
retrain staff. I would say that 80% of that staff was gone … [in] 5 years.
And that’s because they were traditionalists, and much to their credit,
some people came up to me and said ‘this is not what I signed on for. You
have a different model and I’m going to leave because I can’t support
that.’ And then some people left in not so supportive ways.
A director of a center that provides needle exchange services discussed how his
organization was able to use being kicked out of a neighborhood to make leeway on
another project. He attributed it to the fact that his organization, though controversial, is
considered well established and carries weight in the city:
We were having a little bit of trouble a couple of years ago with one of the
sites we drive vans out to. In one of the sites, people in the neighborhood
were saying ‘your people litter, they use and then litter, and we have all of
these needles all over the place and it’s not safe’. So they told the city
about it, and the city said we had to do something about it and we said ‘we
could, but by the way you guys are impeding any kind of progress that we
want to make in terms of getting people in when they are ready to go in.’
Because that’s sort of the way they sell syringe exchange to the
community is ‘this is the bridge to getting people into treatment’. And we
were able to set up a project where they didn’t take the ID [before
providing treatment]. We did all of that [bureaucratic] stuff secondary,
after the person was in. So in 3 months, 47 people got in, where 3 months
earlier we got only 7 people in, because we would have to go do the ID
stuff sorted out first. This way we were doing all of that stuff afterwards.
They were already in a bed [being treated]. And then we would send them
to the different places that they needed.
Other directors described how the fact that their organization is well established and
respected, has allowed it to avoid providing services that are not in line with their
traditional treatment philosophy. For instance, one director of a very large and old private
facility discussed how the organizational philosophy influences service provision and
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hiring decisions:
I am comfortable and in line with [my organization’s] philosophy, which
is an abstinence-based model where it’s understood that harm reduction,
although out there, is dangerous. … The organization espouses a 12-step
philosophy and an abstinence-based model … frankly if an employee
comes here, and is not comfortable with that, or if they come to interview,
it’s not going to work for them here. They are going to cross
philosophically what we are trying do, and it’s not going to work.
These last few quotes suggest that embeddedness of organizations in the institutional
field might be interacting with other factors to influence treatment.

Summary
Analysis of the interviews points to the salience of many factors that may promote
or hinder service provision and the adoption of new practices in substance abuse
treatment. Though these factors can be discussed using the conceptual framework
presented in this thesis, it is evident that they often interact and that the lines are often
blurred. For instance, while managed care (a coercive institutional force) might affect
service provision directly, it is also possible that it interacts with factors such as
counselor credentials, education and recovery status (competing identity logics) to impact
service provision indirectly. It is also possible that managerial attitudes and
embeddedness in the field might be interacting with normative forces to influence service
provision. Furthermore, it seems that some services and practices are adopted faster and
more effectively. These are often practices that are evidence-based, less controversial and
go hand in hand with the treatment philosophy of the organization, its leadership and
societal values.
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Results also point to several other variables that might be influencing services.
For example, while the literature reviewed above suggested that service provision is
influenced by proportions of opiate addicts, dual-diagnosis clients and relapsers,
interviewees pointed to the importance of demographic factors such as gender, pregnancy
status, age, race and religion. Consequently, gender and pregnancy status that were
collected in the NTCS were added to the logistic models, whose results are presented in
the following section.
Finally, throughout the results, and in particular when exploring managerial
attitudes, many interviewees equated methadone with harm reduction (i.e. used the terms
interchangeably), which they did not view favorably. Mangers believed that using
methadone is replacing one addiction for another. Views towards
buprenorphine/naloxone were more accepting. The findings from the interviews suggest
that the factors influencing the provision of methadone might be different than those
influencing the provision of buprenorphine/naloxone. Since the NTCS allows for a
comparison of methadone and buprenorphine/naloxone provision, an additional logistic
model was added to this study in order to explore any possible differences. This model is
presented in the following section and is then compared to the model predicting
buprenorphine/naloxone adoption.

	
  

85	
  

	
  
Quantitative Findings
Descriptive statistics of the variables of interest are presented in tables 6.1 (for the
dependent variables), 6.2 (for independent dichotomous or categorical variables) and 6.3
(for independent continuous variables). Methadone was not originally conceptualized as a
separate dependent variable but is presented in table 6.1 because (1) it was used to
compute medication-assisted treatment, and (2) the qualitative interviews suggested that
views towards methadone and buprenorphine/naloxone and the factors influencing their
adoption might be different. Consequently, logistic models were added to explore the
factors influencing provision of methadone.
Table 6.1 demonstrates that over 90 percent of the centers participating in the
survey indicated they treat patients who are addicted to opiates (369 centers out of a total
of 405 centers). Of these 369 centers that treat patients addicted to opiates, only 65
(17.6%) currently use methadone to treat their clients, and 42 (11.4%) were early
adopters of buprenorphine/naloxone. However, there was almost no overlap between
centers currently providing methadone and those providing buprenorphine/naloxone.
Only four of the centers provided both medications, leading to 103 centers that provided
at least one medication-assisted treatment option (27.9%).

Table 6.1
Descriptive Statistics for Dependent Variables (N=369)

	
  

Variable
Currently provide MAT (methadone or
buprenorphine/naloxone)
Currently treat with methadone
Currently treat with buprenorphine/naloxone
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N
103

%
27.9

65
42

17.6
11.4

	
  
Table 6.2 presents descriptive statistics for independent variables that are
categorical. The vast majority of private centers in the study had state licensing (94%).
Over 60% reported being accredited by JCAHO, and 12.6% reported being accredited by
CARF. About one third of centers reported being owned by a hospital. About 40%
reported participating in research, and nearly the same amount of centers reported using
the ASI during intake. Over 7% of centers reported using ASAM criteria to match their
clients with the appropriate level of care. Finally, almost 40% reported having an active
alumni program.

Table 6.2
Descriptive Statistics for Categorical Independent Variables
Variable
State licensing (coercive)
JCAHO accreditation (coercive)
CARF accreditation (coercive)
Parent organization medical facility (coercive)
Participation in research – ever (milieus)
Use of ASAM to match client with appropriate level of care (milieus)
Use of ASI during intake (milieus)
Active alumni program (milieus)

N
346
226
46
127
143
284
139
144

%
94
61.9
12.6
34.4
39.3
77.6
38
39.2

Table 6.3 presents descriptive statistics for independent variables that are
continuous. Centers reported that an average 19% of funding came from managed care
arrangements and that the average impact managed care arrangements was 2.86 (from a
scale of 0-5). On average, 47% of clients had a dual diagnosis, 54% had relapsed in the
past, 20% had a primary diagnosis of opiate abuse or dependence, 38% were women and
4% of the women were pregnant. The average proportion of counselors at a center
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holding a masters degree or higher was about 40% as was the average proportion of
counselors in recovery. Directors reported being employed at the center for an average of
13.1 years and in the behavioral health field for 19.3 years. The average organizational
age was 23.6 years, and the average size was 68.9 (number of admissions/number of full
time employees). The average center’s orientation to the medical model was 3.51,
average knowledge of CTN 0.83, average alumni activity 0.77 (all on a scale of 0-5).
Finally, centers reported and average of 0.69 on 4 questions designed to measure their
orientation to the 12-step model.

Table 6.3
Descriptive Statistics for Continuous Independent Variables

	
  

Variable

Mean

SD

Min Max

Prop of MC funding (coercive)
Impact of managed care arrangements (mean of 17 items
on a scale of 0-5 each)(coercive)
Orientation to medical/psychiatric model of addiction (05)(identity logics)
Prop of clients with dual diagnosis (normative)
Prop of clients who are relapsers (normative)
Prop of clients with primary diagnosis of opiate
dependence or abuse (normative)
Prop of counselors – MA level or higher (identity logics)
Prop of counselors in recovery (identity logics)
Knowledge of CTN (0-5) (milieus)
Alumni activity (mean of 6 items on a scale of 0-5 each)
(milieus)
Manager tenure at organization (years) (embedded
agency)
Manager tenure in BH field (embedded agency)
Age of organization (embedded agency)
Facility size (# of admissions/FTE's) (embedded agency)
12-step orientation (mean summary of yes responses to 4
questions) (identity logics)
Prop of clients who are women (normative)
Prop of women clients who are pregnant (normative)

0.19
2.86

0.25
0.82

0
0

0.99
4.6

3.51

1.76

0

5

0.47
0.54
0.2

0.25
0.24
0.2

0.01
0.03
0

1
1
1

0.40
0.39
0.83
0.77

0.27
0.25
1.50
1.12

0
0
0
0

0.97
0.92
5
4.83

13.31

7.12

1

33

19.33
23.56
68.89
0.69

7.58
14.07
181.87
0.30

1
1
1.04
0

40
103
2068. 33
1

0.38
0.04

0.16
0.09

0
0

1
0.99
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Two logistic regressions models will regress medication-assisted treatment and
early adoption of buprenorphine/naloxone on the 5 sets of independent variables,
coercive, normative, competing identity logics, milieus and embedded agency factors. As
mentioned above, a third model was added to measure the influence of these factors on
methadone adoption separately.

Factors associated with provision of medication-assisted treatment
Table 6.4 presents results of model 1, regressing provision of medication-assisted
treatment (methadone or buprenorphine/naloxone) on to all hypothesized predictors.
JCAHO accreditation, proportion of clients with primary diagnosis of opiate dependence
or abuse, proportion of clients who are women and past participation in research were all
significantly associated (at the .05 level) with provision of medication-assisted treatment.
Table 6.4 also presents a second model, which included only these significant four
predictors from model 1. All four retained their significance in the second model. In
model 1, state licensing approached significance with provision of medication-assisted
treatment at p<0.1, and it was not included in model 2.
Coercive institutional forces: Of the coercive institutional variables, only JCAHO
accreditation was a significant predictor of medication-assisted treatment provision. The
odds of medication-assisted treatment being provided in an organization were almost four
times greater in organizations that were accredited by JCAHO (AOR=3.85; 95%CI: 2.057.22).
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Normative institutional forces: Two of the normative factors were significant
predictors of medication-assisted treatment provision. A standard increase in the
proportion of clients with a primary diagnosis of opiate dependence or abuse and clients
who are women, increases the odds of medication-assisted treatment being provided by
48 times (AOR=48.03; 95% CI: 12.36-186.54) and 5.4 times, respectively (AOR=5.44;
95% CI: 1.00-29.47). Proportion of dually diagnosed clients, relapsers and women who
were pregnant did not significantly predict provision of medication-assisted treatment.
Salience of milieus: Only past organizational participation in research was a
significant predictor of medication-assisted treatment provision. The odds medicationassisted treatment being provided in an organization almost doubled in organizations that
had previously participated in research (AOR=1.97; 95% CI: 1.16-3.33).
Finally, none of the competing identity logics or embedded agency variables were
found to be significant predictors of medication-assisted treatment provision in private
organizations.
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Table 6.4
Predictors of medication-assisted treatment
Variable

Model 1 (full)
β (SE)

Coercive institutional forces
1.901 (1.107)*
State licensing
1.358 (0.427)***
JCAHO
accreditation
0.578 (0.471)
CARF
accreditation
0.323 (0.341)
Parent
organization
medical facility
Prop of MC
0.286 (0.636)
funding
Impact of
-0.024 (0.035)
managed care
arrangements
Normative institutional forces
Prop of clients
1.054 (0.915)
with dual
diagnosis
Prop of clients
0.967 (0.931)
who are relapsers
Prop of clients
3.974 (0.786)***
with primary
diagnosis of
opiate
dependence or
abuse
Prop of clients
2.317 (1.025)**
who are women
Prop of women
-0.228 (1.431)
clients who are
pregnant
Competing identity logics
Prop of
-0.626 (0.618)
counselors – MA
level or higher
Prop of
0.945 (0.677)
counselors in
recovery
Orientation to
0.104 (0.105)
medical/
psychiatric model
of addiction
12-step
-0.150 (0.604)
orientation

	
  

Adjusted odds
ratio (95% CI)
6.695
(0.763-58.727)
3.890
(1.684-8.986)
1.782
(0.708-4.484)
1.382
(0.708-2.695)

Model 2 (only significant variables)
β (SE)
Adjusted odds
ratio (95% CI)

1.346 (0.322)***

3.845
(2.047-7.224)

3.872 (0.268)**

48.026
(12.364-186.541)

1.694 (0.862)**

5.440
(1.004-29.469)

1.332
(0.382-4.637)
.976
(0.911-1.045)
2.870
(0.476-17.315)
2.631
(0.424-16.321)
53.207
(11.389 248.562)

10.150
(1.360-75.726)
.796
(0.048-13.169)
.535
(0.159-1.800)
2.573
(0.681-9.716)
1.109
(0.902-1.364)
.861
(0.264-2.811)
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Variable
Salience of milieus
Participation in
research – ever
Knowledge of
CTN
Use of ASI
during intake
Use of ASAM to
match client with
appropriate level
of care
Active alumni
program
Alumni activity
Embedded agency
Manager tenure
at organization
Manager tenure
in BH field
Age of
organization
Facility size

Model 1 (full)
β (SE)
0.646 (0.319)**
0.045 (0.202)
0.171 (0.385)
0.180 (0.305)

-0.0767 (0.558)
-0.062 (0.248)

Adjusted odds
ratio (95% CI)
1.909
(1.021-3.568)
1.046
(0.704-1.555)
1.187
(0.558-2.524)
1.197
(0.658-2.179)

Model 2 (only significant variables)
β (SE)
Adjusted odds
ratio (95% CI)
0.677 (0.322)**

1.969
(1.1647-3.331)

.926
(0.310-2.767)
.940
(0.578-1.527)

0.107 (0.249)

1.114
(0.678-1.830)
-0.012 (0.025)
.988
(0.942-1.037)
0.054 (0.123)
1.055
(0.829-1.344)
0.069 (0.160)
1.072
(0.782- 1.469)
No. of imputations: m=20; *p<0.1; **p<0.05; ***p<0.01

Factors associated with provision of buprenorphine/naloxone
Table 6.5 presents results of model 1 regressing provision of
buprenorphine/naloxone on to all hypothesized predictors. Proportion of managed care
funding and proportion of clients with a primary diagnosis of opiate dependence or abuse
were the only two significant variables. They were added to model 2, also presented in
table 6.6, and retained their significance. Three additional variables - impact of managed
care arrangements, proportion of counselors with a masters degree or higher and
orientation to the medical/psychiatric model of addiction - also approached significance
with adoption of buprenorphine/naloxone at p<0.1 and were not included in model 2.
Coercive institutional forces: Of the coercive institutional variables, only
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proportion of managed care funding was a significant predictor of adoption of
buprenorphine/naloxone as a new treatment modality. A standard increase in the
proportion of clients of managed care funding, increases the odds of
buprenorphine/naloxone provision by 10.6 times (AOR=10.58; 95% CI: 3.13-35.76),
suggesting that managed care funding may be freeing up resources that enable
buprenorphine/naloxone adoption. The impact of managed care arrangements only
approached significance in the first model at p<0.1, and was therefore not included in
model 2.
Normative institutional forces: Only proportion of clients with a primary
diagnosis of opiate dependence or abuse was significantly associated with provision of
buprenorphine/naloxone. A standard increase in the proportion of clients with a primary
diagnosis of opiate dependence or abuse, increases the odds of buprenorphine/naloxone
provision by 712% (AOR=7.13; 95% CI: 1.49-34.0). Proportion of dually diagnosed
clients, relapsers, women and women who were pregnant did not significantly predict
provision of buprenorphine/naloxone.
Finally, none of the competing identity logic, salience of milieus or embedded
agency variables were found to be significant predictors of early adoption of
buprenorphine/naloxone in private organizations. However, two of the competing identity
logics factors – proportion of counselors with a masters degree or higher and the
organizations’ orientation to the medical/psychiatric model of addiction – approached
significance in model 1, suggesting they might have a positive effect on provision of
buprenorphine/naloxone.
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Table 6.5
Predictors of early adoption of buprenorphine/naloxone
Variable

Model 1 (full)
β (SE)

Coercive institutional forces
0.284 (1.159)
State licensing
0.237 (0.561)
JCAHO
accreditation
0.049 (0.657)
CARF
accreditation
-0.12 (0.469)
Parent
organization
medical facility
Prop of MC
2.078 (0.803)***
funding
Impact of
-0.088 (0.051)*
managed care
arrangements
Normative institutional forces
Prop of clients
0.765 (1.387)
with dual
diagnosis
Prop of clients
0.574 (1.301)
who are relapsers
Prop of clients
2.189 (1.021)**
with primary
diagnosis of
opiate
dependence or
abuse
Prop of clients
0.925 (1.403)
who are women
Prop of women
-1.018 (2.362)
clients who are
pregnant
Competing identity logics
Prop of
1.604 (0.900)*
counselors – MA
level or higher
Prop of
0.131 (0.986)
counselors in
recovery
Orientation to
1.159 (0.884)*
medical/
psychiatric model
of addiction
12-step
0.542 (0.852)
orientation

	
  

Adjusted odds
ratio (95% CI)

Model 2 (only significant variables)
β (SE)
Adjusted odds
ratio (95% CI)

1.329
(0.137- 12.911)
1.267
(0.422-3.802)
1.050
(0.290-3.805)
.887
(0.354-2.222)
7.990
(1.651-38.681)
.916
(0.828-1.013)

2.359 (0.621)***

10.579
(3.129-35.764)

1.964 (0.797)**

7.126
(1.493-34.002)

2.149
(0.139-33.106)
1.776
(0.139-22.762)
8.926
(1.206-66.047)

2.522
(0.161-39.442)
.361
(0.004-37.064)
4.973
(0.849-29.136)
1.140
(0.164-7.920)
1.268
(0.940-1.712)
1.720
(0.323-9.143)
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Variable
Salience of milieus
Participation in
research – ever
Knowledge of
CTN
Use of ASI
during intake
Use of ASAM to
match client with
appropriate level
of care
Active alumni
program
Alumni activity
Embedded agency
Manager tenure
at organization
Manager tenure
in BH field
Age of
organization
Facility size

Model 1 (full)
β (SE)
-0.234 (0.446)
0.039 (0.263)
0.412 (0.599)
0.651 (0.407)

-0.104 (0.740)
0.382 (0.310)

Adjusted odds
ratio (95% CI)

Model 2 (only significant variables)
β (SE)
Adjusted odds
ratio (95% CI)

.791
(0.330-1.898)
1.040
(0.620-1.743)
1.917
(0.593-6.200)
1.510
(0.680-3.355)
.901
(0.211-3.844)
1.466
(0.789-2.692)

0.170 (0.324)

1.186
(0.621-2.263)
-0.020 (0.036)
.980
(0.914-1.052)
0.142 (0.159)
1.153
(0.843-1.577)
0.097 (0.202)
1.102
(0.843-1.577)
No. of imputations: m=20; *p<0.1; **p<0.05; ***p<0.01

Factors associated with provision of methadone
Table 6.8 presents results of the model regressing provision of methadone on to
all hypothesized predictors. JCAHO accreditation, proportion of clients with a primary
diagnosis of opiate abuse or dependence and women, proportion of counselors with a
masters degree or higher and past participation in research were all significantly
associated with methadone provision at p<0.05. These five variables were retained for
model 2 and all retained their significance. Several other variables were significant at
p<0.1 - CARF accreditation, impact of managed care arrangements, proportion of clients
who are dual diagnosis and use of ASI during intake – and were not included in model 2.
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Coercive institutional forces: Similar to the medication-assisted treatment model,
only JCAHO accreditation was a significant predictor of methadone provision. The odds
of methadone being provided in an organization were almost 6 times greater in
organizations that were accredited by JCAHO (AOR=5.94; 95% CI=2.5-14.1). Two
additional coercive factors - CARF accreditation and impact of managed care
arrangements - approached significance in the first model, and were not included in
model 2. The latter also approached significance in the model predicting
buprenorphine/naloxone adoption, though in the opposite direction
Normative institutional forces: Again, similar to the medication-assisted treatment
model, two of the normative factors were significant predictors of methadone provision.
A standard increase in the proportion of clients with a primary diagnosis of opiate
dependence or abuse and clients who are women, increases the odds of medicationassisted treatment being provided by 55 times (AOR=55.05; 95% CI: 11.28-268.68) and
14 times, respectively (AOR=14.35; 95% CI: 1.86-110.67). Proportion of dually
diagnosed clients approached significance, while relapsers and women who were
pregnant did not significantly predict provision of methadone, though.
Competing identity logics: This was the only model in which an identity logics
factor was found to be significant. Interestingly, the effect was negative. For every
standard unit increase in the proportion of counselors with a master’s degree or higher,
the likelihood of offering methadone decreased by 81% (AOR=0.19; 95% CI: 0.05-0.63).
Salience of milieus: Once again, similar to the medication-assisted treatment
model, only past organizational participation in research was a significant predictor of
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methadone provision. The odds of methadone being provided in an organization nearly
tripled in organizations that had previously participated in research (AOR=2.8; 95% CI:
1.47-5.31). Use of ASI during intake approached significance (p<0.1) and was not
included in the final model
Finally, similar to both previous models, none of the embedded agency variables
were found to be significant predictors on methadone provision in private organizations.

Table 6.6
Predictors of methadone adoption
Variable

Model 1 (full)
β (SE)

Coercive institutional forces
2.444 (0.738)***
JCAHO
accreditation
1.353 (0.744)*
CARF
accreditation
0.513 (0.483)
Parent
organization
medical facility
Prop of MC
-1.489 (1.289)
funding
Impact of
0.089 (0.053)*
managed care
arrangements
Normative institutional forces
Prop of clients
2.495 (1.477)*
with dual
diagnosis
Prop of clients
1.571 (1.386)
who are relapsers
Prop of clients
5.242 (1.123)***
with primary
diagnosis of
opiate
dependence or
abuse
Prop of clients
3.876 (1.577)**
who are women
Prop of women

	
  

-0.714 (2.035)

Adjusted odds
ratio (95% CI)
10.283
(3.190-33.141)
2.142
(0.622-6.930)
1.352
(0.569-3.069)

Model 2 (only significant variables)
β (SE)
Adjusted odds
ratio (95% CI)
1.782 (0.441)***

5.942
(2.504-14.103)

4.008 (0.806)***

55.046
(11.277-268.684)

2.664 (1.042)**

14.350
(1.860-110.669)

0.162
(0.022-1.175)
1.038
(0.951-1.133)
3.765
(0.349-40.599)
4.386
(0.433-44.436)
69.649
(11.269-430-489)

16.506
(1.225-222.365)
1.642
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Variable

Model 1 (full)
β (SE)

clients who are
pregnant
Competing identity logics
Prop of
-2.017 (0.883)**
counselors – MA
level or higher
Prop of
0.660 (1.042)
counselors in
recovery
Orientation to
0.019 (0.157)
medical/
psychiatric model
of addiction
12-step
-1.265 (0.910)
orientation
Salience of milieus
1.113 (0.491)**
Participation in
research – ever
Knowledge of
0.154 (0.312)
CTN
-0.956 (0.579)*
Use of ASI
during intake
-0.103 (0.464)
Use of ASAM to
match client with
appropriate level
of care
-0.326 (0.872)
Active alumni
program
Alumni activity
-0.438 (0.427)
Embedded agency
Manager tenure
at organization
Manager tenure
in BH field
Age of
organization
Facility size

Adjusted odds
ratio (95% CI)
(0.074-36.531)
0.117
(0.026-0.514)

-1.686
(0.625)***

0.185
(0.054-0.631)

1.029 (0.323)***

2.798
(1.474-5.310)

1.717
(0.331-8.911)
0.971
(0.751-1.256)
0.353
(0.084-1.494)
3.300
(1.462-7.451)
1.097
(0.655-1.836)
0.832
(0.3434-2.071)
1.233
(0.579-2.625)
1.370
(-.328-5.719)
0.995
(0.270-1.118)

1.037
(0.547- 1.966)
0.008 (0.549)
.995
(0.936-1.059)
-0.064 (0.182)
0.924
(0.677-1.261)
-0.048 (0.255)
1.049
(0.712-1.546)
No. of imputations: m=20; *p<0.1; **p<0.05; ***p<0.01

	
  

Model 2 (only significant variables)
β (SE)
Adjusted odds
ratio (95% CI)

0.025 (0.373)
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Summary
Table 6.7 summarizes only the significant variables from all the models and their
direction. According to the table there are many independent variables (including all of
the embedded agency variables) that do not significantly predict any of the dependent
variables that were explored. However, several of the variables significantly predict more
than one variable.
Coercive institutional forces: JCAHO accreditation was a significant predictor of
both medication-assisted treatment provision and methadone provision separately, but not
of buprenorphine/naloxone adoption. Proportion of managed care funding, on the other
hand, was a significant predictor of buprenorphine/naloxone adoption but not of
medication-assisted treatment and methadone provision. Impact of managed care
arrangements approached significance in both the buprenorphine/naloxone and
methadone models, though in the opposite direction. State licensing approached
significance only in the medication-assisted treatment model, while CARF accreditation
approached significance only in the methadone model. Having a medical facility as a
parent organization was not significant in any of the models.
Normative institutional forces: As expected, proportion of clients with a primary
diagnosis of opiate dependence or abuse positively predicted all three dependent
variables. Proportion of women clients, a variable added to the analysis following the
qualitative interviews, was a significant predictor of both medication-assisted treatment
provision and methadone provision separately. This finding supported the theme brought
up by several of the interviewees. Proportion of clients with dual-diagnosis approached
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significance only in the methadone model, while proportion of relapsers and pregnant
women was not significant in any of the models.
Competing identity logics: Proportion of counselors with a master’s degree or
higher was a significant negative predictor in the methadone provision model and
approached significance in the opposite direction in the buprenorphine/naloxone model.
Orientation to the medical/psychiatric model of addiction approached significance in the
buprenorphine/naloxone model but not the other two models, while proportion of
counselors in recovery and orientation to 12-step ideology were not significant in any of
the models.
Salience of milieus: Only past organizational participation in research was a
significant predictor of medication-assisted treatment provision, as well as of methadone
provision separately. Use of ASI during intake approached significance in the model
predicting methadone provision, while use of ASAM, knowledge of CTN, having an
active alumni program and the level of alumni activity were not significant predictors in
any of the models.
Embedded agency: None of the embedded agency variables were found to be
significant predictors of any of the dependent variables.
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Table 6.7.
Significant associations of hypothesized predictors
Variable

Medication-assisted
treatment

Buprenorphine/
naloxone

Methadone

Coercive institutional forces
(+)
State licensing
+
+
JCAHO accreditation
(+)
CARF accreditation
Parent organization medical facility
Prop of MC funding
+
Impact of managed care arrangements
(-)
(+)
Normative institutional forces
Prop of clients with dual diagnosis
(+)
Prop of clients who are relapsers
Prop of clients with primary diagnosis
+
+
+
of opiate dependence or abuse
Prop of clients who are women
+
+
Prop of women clients who are
pregnant
Competing identity logics
Prop of counselors – MA level or
(+)
higher
Prop of counselors in recovery
Orientation to medical/psychiatric
(+)
model of addiction
12-step orientation
Salience of milieus
+
+
Participation in research – ever
Use of ASAM to match client with
appropriate level of care
(+)
Use of ASI during intake
Knowledge of CTN
Active alumni program
Alumni activity
Embedded agency
Manager tenure at organization
Manager tenure in BH field
Age of organization
Facility size
*(-) or (+) indicate the variable approached significance in model 1 at p<0.1 and was not subsequently
included in model 2.
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Chapter 7
Summary and Discussion
Despite the demonstrated effectiveness of both methadone and
buprenorphine/naloxone in the treatment of opioid dependence, only 17.5 percent of
private treatment facilities offer methadone to their clients, while a little over 10% offer
buprenorphine/naloxone. Interestingly, only four centers provided both medications.
Previous studies, conducted within NIDA’s Clinical Trails Network (CTN), indicated that
the odds of buprenorphine/naloxone adoption were significantly greater in programs
offering methadone (Knudsen et al., 2009; Koch, Arfken, & Schuster, 2006). However,
this was not sustained at a 24-month follow-up when the availability of methadone was
no longer associated with buprenorphine/naloxone adoption (Knudsen et al., 2009),
suggesting that while provision of medication-assisted treatment in general was low,
buprenorphine/naloxone was adopted by organizations that did not previously offer
pharmacotherapies.
Neoinstitutional forces, as well as institutional logics influence provision of
medication-assisted treatment in substance abuse treatment facilities. Several factors
emerged as significant predictors of the dependent variables. Only one factor, the
proportion of clients with a primary diagnosis of opiate dependence, was positively
associated with all dependent variables. Predictors for medication-assisted treatment were
very similar to those of methadone alone; all four factors associated positively with
mediation-assisted treatment in general were also positively associated with methadone
separately. It is important to keep in mind that medication-assisted treatment was
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comprised only of methadone and buprenorphine/naloxone, and that more facilities
provided methadone. However, predictors of methadone provision were not similar to
those for the early adoption of buprenorphine/naloxone.
Coercive institutional forces: Both qualitative and quantitative results indicate
that coercive forces, such as managed care and accreditation, play a role in the provision
of medication-assisted treatment.
Managed care: The proportion of managed care funding was a positive
significant predictor of early adoption of buprenorphine/naloxone. Scholars have found
how managed care’s propensity to curtail costs has resulted in the reduction of service
provision, mostly in public facilities. Managed care regulation was negatively correlated
with treatment intensity (Lemak & Alexander, 2001) and the number of services provided
(Corcoran & Vandiver, 1996; Gold, Hurley, Lake, Ensor & Berenson, 1995; Olmstead,
White & Sindelar, 2004). It was also found to limit autonomy of the provider (Alexander
& Lemak, 1997; Mechanic, Schlesinger, & McAlpine, 1995; Schlesinger, Dorward, &
Epstein, 1996; Schwartz & Wetzler, 1998), not increase technical efficiency in service
provision (Alexander, Wheeler, Nahra & Lemak, 1998) and increase relapse rates (Sosin,
2005).
However, the findings in this study suggest that the availability of managed care
funds promotes evidence-based innovation, which is supported by recent literature.
Roman and Johnson (2002) found that early adoption of naltrexone was positively and
significantly associated with the percentage of the center's caseload covered by managed
care programs. Also, in their study of early adoption of buprenorphine/naloxone,
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Knudsen and colleagues (2006) found that private centers were significantly more likely
than public centers to report current use of buprenorphine/naloxone. It is possible that
managed care is more sympathetic to innovative interventions like
buprenorphine/naloxone because there is data to show that it will translate to better
results in efficient private care settings, thus curtailing costs in the long run.
Managed care firms have the option is to deny care (or various aspects of care), and they
may be authorizing certain types of clients and treatment options over others.
Interestingly, the impact of managed care arrangements (how involved they are in
organizational decision-making processes) approached significance in the first model,
suggesting a possible opposite effect on buprenorphine/naloxone provision. It is possible
that in organizations where managed care is more involved in day-to-day operations,
adoption becomes increasingly challenging. Future research needs to examine possible
differential beliefs about private versus public facilities and medication-assisted treatment
on the part of managed care funders.
Accreditation: In the qualitative interviews accreditation was mostly viewed as a
hindrance, as regulatory agencies sometimes force agencies to take measures and provide
services that are not in line with the current norms of the organizations or the treatment
modality. The quantitative results showed that JACHO accreditation significantly
associated with both medication-assisted treatment provision and methadone provision
separately, though not of early adoption of buprenorphine/naloxone. It is important to
note here again that organizations who provide methadone, must be licensed to do to. The
same is not true for buprenorphine/naloxone which is less tightly controlled and can be
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prescribed by many qualified doctors in primary care settings. These findings are only
partially consistent with previous research, which found that accreditation increases
service provision of HIV services to seropositive clients (Ghose, 2006) as well as early
adoption of buprenorphine/naloxone (Knudsen et al., 2006). However, it lends support to
the hypothesis emerging from the qualitative interviews that the factors influencing
adoption of each drug are not the same; while funding is essential for early adoption of
buprenorphine/naloxone, accreditation may be a more salient factor in the provision of
methadone.
Normative institutional forces: The salience of client characteristics in
influencing adoption and provision of services was supported by both the qualitative and
quantitative findings. Managers provided multiple detailed examples of how
organizations adapt and change to cater to the needs of certain types of clients. One of the
main themes discussed was how treating opiate-addicted women, particularly pregnant
women, forces the organization to be more open to providing methadone (or referring to
organization who already provide methadone). Subsequently, the proportion of women
treated by the organization was added to the logistic analysis. Though this variable has
not previously been explored, it emerged as a significant predictor of both medicationassisted treatment provision and methadone provision, but not of
buprenorphine/naloxone.
As expected, proportion of clients with a primary diagnosis of opiate dependence
or abuse positively predicted all three dependent variables. This is consistent with
previous research (Ghose, 2006; Knudsen et al., 2006), and lends further support to the
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hypothesis that clients, who comprise the ‘raw material’ of human service organizations,
dictate the types of treatment and service technologies adopted by the organization
(Hasenfeld, 1992). Organizational theorists have noted that institutional norms, standards
and expectations shape and structure processes (Barley & Tolbert, 1997; Cooney, 2007;
Orlikowski, 2000). Organizations and institutions thus both constrain agency, ideology
and materials but are also subject to them (Giddens, 1984; Sewell, 1992). 	
  
Competing identity logics: Managers often described ideological clashes within
the substance abuse treatment field. Many traced the source of these clashes to the
merging of the substance abuse and mental health fields. Similar to work by D’Aunno
and colleagues (1991), managers discussed how people in the field are subject to two
beliefs systems, or sets of ideological logics, which are often at odds. They argued that
that people coming from the substance abuse treatment field are more traditional and
more likely to adhere to the 12-step/abstinence/AA model of addiction, often as a result
of their personal experience with substance abuse, while people coming from the mental
health field hold a more medical orientation towards addiction and are often more
educated. Though not mutually exclusive, is was suggested that those with a background
in mental health education favor the use of medication-assisted treatment, while those
with a substance abuse background prefer total abstinence from all substances,
methadone included. However, when buprenorphine/naloxone was discussed, it was
viewed as a short-term crutch, and more acceptable than methadone among those who
identified themselves as belonging to the ‘old-school’ model.
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Interestingly, the logistic analysis painted a slightly different picture. The
proportion of counselors with a master’s degree or higher was a significant negative
predictor in the methadone provision model and only approached significance in the
positive direction in the buprenorphine/naloxone model. A possible explanation for these
finding is that people with higher education have better access to and knowledge of
research on innovative approaches to treatment. Therefore, they may have been aware of
the new medication available, buprenorphine/naloxone, and supportive of introducing it
as a treatment option, perhaps even offering it instead of the already available alternative,
methadone.
As previously mentioned, many of the managers who were interviewed expressed
differential orientations towards methadone and buprenorphine/naloxone. While
methadone was often viewed as replacing one addictive substance with another,
buprenorphine/naloxone was viewed as an innovative medication for the treatment of
addiction. Furthermore, ‘methadone’ was often used interchangeably with ‘harm
reduction’, which was not viewed favorably by many managers. Scholarship indicates
that methadone maintenance is often considered a controversial issue (McLellan, 2003)
and can be considered a harm reduction strategy (Weschberg & Kasten, 2007).
Riley and O’hare (2000) summarized some of the main barriers to harm reduction
practices. The main argument is that people who would not otherwise use drugs might
begin doing so if they perceive that it is safe and legal (or at the least not criminalized).
They also argued that currently society does not accept drug use as a ‘legitimate form of
risk taking’, thus the moral stance is prevalent. These notions, in addition to laws already
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in place and to lack of knowledge in the general public regarding the true nature of
substance abuse, leads to a political climate which is less than supportive of efforts to
implement harm reduction measures (Riley & O’Hare, 2000), possibly including
methadone. At the organizational level, Rosenberg and Phillips (2003) that the low rates
of adoption of methadone, which were conceptualized as a form of harm reduction in
their study, were attributed mostly to lack of consistency with agency philosophy, and to
a lesser degree, to a lack of resources and funding. Buprenorphine/naloxone was not
included in their study as a form of harm reduction, also supporting the need to
distinguish between the two substances, in research and in practice. Future research
should explore trends in the adoption as well as discontinuation of the two substances.
This finding, though surprising, lends additional support to the merit of exploring
methadone and buprenorphine/naloxone adoption separately.
Salience of milieus: Research has called for the examination of the role of
networks and interorganizational relationships in influencing medication adoption
(Ducharme et al. 2007). Findings from the qualitative interviews indicate that research
networks are important in promoting adoption. Access and participation in research and
training were viewed as critical in the process of adopting new practices and in
determining service provision. However, knowledge of evidence-based practice was not
enough. Many stressed that in order for their organization to provide a service or consider
adding an innovation to their menu of available treatment options, it must be consistent
with the organizational philosophy.
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The logistic analysis also indicated that research networks have a role in service
provision. Past organizational participation in research was a significant predictor of
medication-assisted treatment provision, as well as of methadone separately. Though
further research in this area is needed, previous literature has found that units whose
directors were linked to external professional networks were more likely to provide HIV
prevention, have collaborative relationships with other agencies and survive over time
(D’Aunno, 2006). Knudsen and colleagues (2009) also linked the adoption of
buprenorphine/naloxone to involvement in a buprenorphine/naloxone protocol. This in
turn, carries with it significant policy and practice implications.
Embedded agency: None of the embedded agency variables were found to be
significant predictors of any of the dependent variables. In previous research,
organizational size in particular, has been consistently found to be a positive predictor of
medication adoption in general and buprenorphine/naloxone adoption in particular
(Knudsen et al., 2006, 2007a; Duchrame & Roman, 2009). Two possible explanations are
offered for the lack of statistical significance of these factors in predicting the dependent
variables. First, the data set used in this study only captures the universe of private
treatment facilities, and it is likely that organizational characteristics such as age and size
will emerge as significant predictors of medication-assisted treatment when exploring the
whole universe of substance abuse treatment facilities. Second, it is possible that the
operationalization of embedded agency (size and age for the organization and tenure for
managers) did not capture the complexity of the idea that individuals and organizations
may be influencing their institutional environment.
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In sum, the multiple factors discussed by decision-makers, support the use of a
comprehensive conceptual framework to study adoption of practices, particularly in a
field that is as fragmented and value-laden as substance abuse treatment. The large,
nationally representative data set used for this study, combined with multiple imputation
procedures to handle missing data, allowed for inclusion of multiple predictors in the
analysis, thereby addressing one limitation of previous research (e.g. as suggested by
Knudsen et al., 2009).
Implications for organizations:
The results of this study have several implications for substance abuse treatment
organizations:
Managed care funding was positively associated with early adoption of
buprenorphine/naloxone, suggesting that managed care encourages early adoption of
innovation. This suggests that managed care views buprenorphine/naloxone as a
medication and is therefore more likely to fund it. This point carries with it important
implications for managers who need to make decisions on how to fund treatment for
clients. Decision makers in private facilities looking to add a medication to their regime,
should be aware that buprenorphine/naloxone might be an easy sell to managed care; the
goal of managed care firms is to save money, and buprenorphine/naloxone is a cheaper
treatment avenue than residential care or detoxification for clients suffering from opioid
dependence. With this in mind, managed care arrangements and their involvement in
organizational professional decision-making processes should be carefully reviewed, and
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further research is a needed in this area, particularly research exploring how managed
care funders view different medication-assisted treatments.
Organizations encounter different types of clients and they must cater their
services to meet clients’ unique needs. This requires specialized training oriented towards
innovations and evidence-based practices. For instance, working with opiate addicts
requires training on available medications for opiate addiction. Having managers attend
research conventions, fostering research connections with universities and research
centers and participating in research can, at the very least, orient managers to innovations
in the field, thereby adding to their knowledge and perhaps shaping attitudes towards
treatment options that are more controversial.
Implications for policy:
Several implications for policy also arise from this study:
Accreditation by JCAHO was positively associated with adoption of medicationassisted treatment. However, there are still large portions of private facilities that are not
licensed by JCAHO, suggesting there is room for growth in this area. This implication is
supported by findings of previous research, which found that facilities accredited by
JCAHO were more likely to provide primary care and mental health services (Friedmann
et al., 1999; D’Aunno, 2006), physical exams and routine medical care (Durkin, 2002),
use antidepressants (Knudsen et al., 2007b) and be early adopters of
buprenorphine/naloxone (Knudsen et al, 2006). It is important to note that this is a crosssectional survey, and therefore it is also possible that the adoption of practices predates
organizational accreditation. However, as accreditation has consistently been shown to
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promote service provision, organizational efforts to gain accreditation should be
supported. Furthermore, licensing and accreditation agencies can monitor training and
research efforts to help organizations achieve better outcomes and increase their
efficiency.
Being involved in research milieus facilitates the uptake of innovative
medication-assisted treatment. Organizations should also aspire to increase their
participation in research, and managers should be made part of academic-provider
partnerships - such as has been done by the National Institute on Drug Abuse (NIDA) in
their Clinical Trial Network (CTN) program. Though this involvement may not
necessarily encourage managers to become more positively disposed towards certain
controversial evidence-based practice (methadone), the results of this research indicate
that being involved in research networks makes them more likely to adopt others
(buprenorphine/naloxone). Furthermore, involvement in these networks can help
organizations shift to outcome oriented thinking. A focus on outcomes, which are
directed towards the unique, needs of clients, can in turn help promote better quality of
care, and is in line with the increasing demands for transparency and accountability in
human service organizations in general and substance abuse treatment organizations in
particular, shrinking social service budgets and increased commitment to improved
services and results-oriented management. (McLellan, Carise, & Kleber, 2003; McLellan,
Chalk, & Bartlett, 2007; McLellan, Kemp, & Brooks, 2008; McLellan, McKay, Forman,
Cacciola, & Kemp, 2005).
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Utility of conceptual model
The use of theory in the study of substance abuse treatment is limited. With the
notable exception of D’Aunno and colleagues (D’Aunno et al., 1991; D’Aunno et al,
1999), and very recent work by Roman and colleagues (Savage et al., 2012) most
scholars do not employ a comprehensive conceptual framework to identify organizational
predictors, or to interpret results. As a result, research on organizational research in
substance abuse treatment has tended to focus on top-down institutional forces shaping
treatment.
Utilizing a comprehensive framework, such as the one in this study, allows for
organization of the institutional, organizational and individual forces at play in decisions
regarding service provision. Moreover, it allows for exploring certain variables that have
not been highlighted in previous research that may be salient. The conceptual framework
can help highlight important dynamics that are taking place in the field. For example, the
salience of research milieus was predicted by the conceptual model, yet is not often
included as a factor of interest in organizational studies in the field. The importance of
institutional logics and of individuals embedded in organizations to facilitate
organizational change is another example, a theme highlighted in the qualitative results.
The conceptual model may also be utilized to explain anomalous results. For
instance, while managed care has often been found to undermine service provision in
previous research, was beneficial for the adoption of buprenorphine/naloxone in this
research. Use of the conceptual model allows us to theorize regarding possible
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explanations, such as how the influence of coercive forces aligns with the use of efficient
technology.
Limitations
This study has several limitations. First, While NTCS is a nationally
representative dataset, rich in organizational and institutional variables it was not
constructed with a specific conceptual framework in mind or with the goal of testing
theory. Therefore, measuring concepts such as those discussed here was not ideal. Future
research needs to address these complex concepts and others by including appropriate
measures.
A second related limitation is that the NTCS included primarily organizational
variables, and did not account for the possible role of agency. Future research should
explore the role of individuals within the organization (from different positions and
professions). As noted by Oliva and colleagues (2011), considerably less attention has
been paid to research examining patient perspectives, knowledge, and attitudes regarding
medication-assisted treatment in general and the various medications in particular.
Additional qualitative work might also be useful in exploring these issues.
Third, the NTCS included only private facilities, which were uniquely defined as
those receiving less than 50% of their annual operating revenues from government grants
or contracts. It is possible that organizations do not characterize themselves based on this
criterion. A possible alternative might be to use the actual proportion of public or private
funding as continuous measures, rather than forcing a dichotomous public/private
distinction in the current economic environment. Regardless, future research should
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include the entire universe of facilities, allowing for a comparison of public and private
facilities when appropriate.
The public vs. private comparison has been a major variable of concern in
previous literature, and previous studies have demonstrated that private centers were
more likely to be early adopters of buprenorphine/naloxone and provide methadone to
their clients (Knudsen et al., 2006; Knudsen, Abraham, & Roman, 2011), suggesting that
the low rates of adoption in private facilities might be even lower for substance abuse
treatment organizations in general. Furthermore, it is likely that the public/private
division, which could not be addressed in this study, may interact with some of the
factors explored in this study, to impact service provision and innovation adoption.
Fourth, the available data are cross-sectional and therefore any analysis cannot
include historical trends or changes. Any analysis yields correlational results and causal
inferences cannot be made. Future research that utilizes longitudinal data and analysis of
trends is needed, for instance, in the comparison of adoption and discontinuation of
methadone compared to buprenorphine/naloxone.
Finally, I utilize multiple imputations to account for missing data. Though the
literature is in agreement that this is one of the preferred methods for dealing with
missing values in order to keep the sample unbiased and as large as possible (Allison,
2010; Enders, 2010) it must be noted that two of the variables that were significant in the
models – proportion of managed care funding and proportion of counselors with a
masters degree or higher – had a relatively high percentage of missing data (20.9 and
20.6, respectively). Biased estimations increase as the rates of missing data increase,
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though accurate estimates were found as long as missingness was up to approximately
25% (Enders, 2010).
Suggestions for future research
Based on the results of this study, both quantitative and qualitative, several
additional suggestions for future research are offered. One avenue for future research
might be to explore harm reduction practices other than methadone to see if findings from
this study are consistent and if methadone can conceptually be categorized as a harm
reduction practice.
Themes emerging from the qualitative interviews also suggest that future research
should examine attitudes towards adoption of specific innovations (e.g. attitudes of
clients, employees, decision-makers), individual and organizational decision-making
processes, patient preferences, as well as public policy and societal-level barriers to
adoption.
In general, the use of an organizing framework as well as incorporation of
qualitative methods can help point to additional factors that might be influencing the
adoption of practices, as was the case with proportion of women in this study. A next
logical step, would be to design and conduct studies that manipulate these organizationallevel variables to promote adoption of evidence-based practices in general, and
medication-assisted treatment in particular, with the goal of improving the quality of
services in the field. The widespread adoption of medication-assisted treatments, new and
established, requires large-scale organizational changes that can only be achieved through
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comprehensive and multi-faceted initiatives that take into account all levels of
organizational life.
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Appendix 1: Semi-structured qualitative interview
for managers of substance abuse treatment facilities
Services
1) Could you tell us about the type of services offered at this facility?
2) Follow-up: Could you tell us about the following services at this facility?
a) Substance use treatment services
b) Mental health services
c) Medical services
d) HIV-related services
e) Supplemental services (transportation, childcare, housing)
3) Are there areas that you feel this facility excels in providing services? If you had the
resources, what type of services would you like to add?
4) What do you feel about evidence-based practice/services? Do you have ways to link
research with practice?
Ideology/Orientation
5) Could you tell us about your views about how best to treat substance use
6) Follow-up: Explore disease model vs. harm reduction model. Explore chronic vs
acute conceptualization of substance use.
7) Do you think being an ex-user is preferable in a counselor? If so why, if not, why
not?
8) What are your views on brief treatment? Outpatient treatment? Residential treatment?
Methadone maintenance/opioid replacement therapy? Harm reduction vs abstinence?
9) Can you tell us about venues (meetings, conferences, gatherings) where you meet
other facility managers, counselors and members of the treatment community in
Philadelphia?
10) Follow-ups: Could you tell us about what gets discussed at these venues? What is the
level of contact you have with fellow members of the treatment community?
11) In your opinion, how prevalent/popular in the treatment community are views
supporting: a)Harm reduction, b) abstinence, c) using ex-addicts as counselors, d)
using licensed professional counselors d) using AA/NA groups, e) using brief
treatment modalities, f) using methadone maintenance treatment?
12) How do you find out/keep track about what views are prevalent in the treatment
community?
Funding?
13) What are the funding streams for your facility? What proportion of funds are
government (explore type of gov funding- Medicaid, managed medicaid etc); clientpaid fees per session; managed care;
14) Have you seen a change in funding during the last 5-7 years? What are they? How has
managed care funding affected you?
Personnel
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15) What is the size of the staff at your facility? How many counselors? How many
degreed counselors, paraprofessionals?
16) What is your opinion about ex-users as counselors? Degreed counselors providing
treatment?
17) How does funding influence the personnel you hire?
Clients
18) What is the demographic profile of your clients? Do you see more of a certain type of
clients that others? How do you feel these clients are best treated?
19) Does funding affect the types of clients the facility treats? How do you retain clients
who need more long-term care in the present funding environment?
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